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ABSTRACT OF THE DISSERTATION
PET/MR Imaging of Hypoxic Atherosclerotic Plaque Using 64Cu-ATSM
by
Xingyu Nie
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2017
Professor Pamela K. Woodard, Chair
Professor Suzanne Lapi, Co-Chair
It is important to accurately identify the factors involved in the progression of atherosclerosis
because advanced atherosclerotic lesions are prone to rupture, leading to disability or death.
Hypoxic areas have been known to be present in human atherosclerotic lesions, and lesion
progression is associated with the formation of lipid-loaded macrophages and increased local
inflammation which are potential major factors in the formation of vulnerable plaque. This
dissertation work represents a comprehensive investigation of non-invasive identification of
hypoxic atherosclerotic plaque in animal models and human subjects using the PET hypoxia
imaging agent 64Cu-ATSM.
We first demonstrated the feasibility of 64Cu-ATSM for the identification of hypoxic
atherosclerotic plaque and evaluated the relative effects of diet and genetics on hypoxia
progression in atherosclerotic plaque in a genetically-altered mouse model. We then fully validated
the feasibility of using 64Cu-ATSM to image the extent of hypoxia in a rabbit model with
atherosclerotic-like plaque using a simultaneous PET-MR system. We also proceeded with a pilot
clinical trial to determine whether 64Cu-ATSM MR/PET scanning is capable of detecting hypoxic
carotid atherosclerosis in human subjects.
In order to improve the 64Cu-ATSM PET image quality, we investigated the Siemens HD (highdefinition) PET software and 4 partial volume correction methods to correct for partial volume
effects. In addition, we incorporated the attenuation effect of the carotid surface coil into the MR
attenuation correction μ-map to correct for photon attention.
In the long term, this imaging strategy has the potential to help identify patients at risk for
cardiovascular events, guide therapy, and add to the understanding of plaque biology in human
patients.

xiii

Chapter 1: Introduction
1.1 Significance
Cardiovascular atherosclerosis is the leading cause of death worldwide despite primary and
secondary prevention. Cardiovascular disease impacts the public broadly and affects an estimated
80 million people in the United States (1). Each year more than a million people in the United
States experience a sudden cardiac event (acute coronary syndrome or sudden cardiac death) and
an additional 700,000 experience stroke (2). Diabetes mellitus, another leading cause of morbidity
and mortality in Western nations, is strongly associated with accelerated atherosclerosis – 86% of
patients with newly diagnosed diabetes have atherosclerosis and as blood glucose levels increase,
the incidence of clinical or preclinical atherosclerosis also increases (3).
Cardiovascular atherosclerosis is a systemic degenerative and inflammatory vascular disease that
develops over decades, leading to advanced lesions characterized by a lipid core separated from
the lumen by a fibrous cap. It has been recognized that plaque composition more than the degree
of luminal stenosis determines the risk of acute clinical events (e.g. stroke, myocardial infarction)
(4). Macrophage-rich plaques with a thin fibrous cap, large lipid core, and abundance of leaky
microvessels tend to be more vulnerable (4). The rupture or erosion of the fibrous cap in vulnerable
plaque may lead to thromboembolization and arterial occlusion (5, 6).
There is growing evidence that hypoxic plaques are more likely to develop angiogenesis which
leads to thrombosis (2, 3). Additionally, there is some suggestion that plaque hypoxia is increased
in patients who are diabetic (7, 8). However, at present there is a lack of an effective approach to
monitor non-obstructive asymptomatic but potentially unstable atherosclerosis. It will be

1

significant to find a competent, inexpensive, non-toxic PET imaging agent to detect potentially
unstable atherosclerosis, and ideally, have it be FDA approved for commercialization.

1.2 Innovation
This study may represent the first use of Cu-ATSM, the first bis(thiosemicarbazone) complexes
demonstrated to exhibit hypoxia selectivity (9-11), to target hypoxic atherosclerosis. We
hypothesize that the tumor hypoxia PET imaging agent 64Cu-ATSM can be able to detect hypoxia
in atherosclerotic plaque in animal and human subjects using the PET-CT or PET-MRI imaging
system.
Despite the relatively extensive use of Cu-ATSM in oncology (12-14), its use in cardiology has so
far been limited. Retrospective review of PET-CT examinations in cervical cancer patients imaged
with

64

Cu-ATSM at our institution revealed

atherosclerosis. Although

18

64

Cu-ATSM uptake in regions corresponding to

F-fluorodeoxyglucose (FDG), an agent used to image metabolic

activity as a glucose analog, is well-described as an agent in atherosclerosis imaging (15) and has
been shown to detect vascular atheroma (15), it provides limited value for evaluating the coronary
arteries due to the confounding effects of myocardial uptake of the radiotracer. If successful, 64CuATSM imaging would overcome this limitation.

18

F-FMISO is one of the most commonly used

investigational PET agents for the measurement of tumor hypoxia (16). However compared to
64

Cu-ATSM, it has two major disadvantages: low cellular uptake and slow washout from normoxic

tissue (16). The more efficient uptake and washout kinetics of

64

Cu-ATSM in hypoxic and

normoxic cells offers the possibility of a fast and efficient means of detecting hypoxia by PET
imaging.

18

F-EF5 has also been studied to detect hypoxic plaques in atherosclerotic mice by ex

vivo methods, but the slow blood clearance and high adventitial uptake limit its value for in vivo
imaging of atherosclerosis (17). These anecdotal findings raised the suggestion that 64Cu-ATSM
2

is a more discriminating agent and led us to perform some basic preclinical experiments to assess
our hypothesis.
Nevertheless, it has been shown that 64Cu-ATSM is a valid PET hypoxia marker in some tumor
types, but not for all (18). This cell–dependent hypoxia selectivity of 64Cu-ATSM, along with its
time-dependent spatial distribution and retention kinetics suggested in other studies, challenges
the use of 64Cu-ATSM as a universal PET hypoxia marker (18-23) . Therefore, further studies are
needed to validate the retention behavior for this PET marker in hypoxic atherosclerotic plaques.
In this dissertation research, we imaged the hypoxic atherosclerosis in both animal and human
subjects in vivo using

64

Cu-ATSM, and following removal of the diseased sections in animals,

assessed its histopathologic characteristics ex vivo. In addition, we used the hypoxia-specific dye
pimonidazole (PIMO). It is a 2-nitroimidazole containing a basic, piperidine moiety and reduced
in cells with low oxygen tension (pO2 ≤ 10 mm Hg). The resulting PIMO derivatives form protein
adducts, which can be detected by immunostaining (24). This agent primarily has been used in
oncologic specimen assessment (25) and only recently in assessment of atherosclerosis (26).
Another highly innovative aspect to this study is our work to image these subjects simultaneously
by MR and PET in a newly acquired state-of-the-art PET-MRI system (Biograph mMR, Siemens,
Erlangen, Germany). This system, which was FDA approved in June, 2011, is one of only several
currently operational in the United States. This system uses MRI for attenuation correction as well
as diagnostic imaging allowing for simultaneous co-registered high-resolution 3 Tesla MR
imaging of rabbit’s femoral artery or human’s carotid atherosclerosis anatomy and

64

Cu-ATSM

PET imaging. Lastly, this study incorporated advanced partial volume correction techniques and
coil-attenuation correction method for PET image quality improvement.

3

1.3 Specific Aims
This research evaluated the PET hypoxia imaging agent

64

Cu-ATSM for non-invasively

identifying and characterizing hypoxic atherosclerotic plaque. In the long term, this imaging
strategy will help identify patients at risk for cardiovascular events, guide therapy, and study
plaque biology in human patients.
As such, in the dissertation work, a dedicated, start-to-finish process for a

64

Cu-ATSM

simultaneous PET-MRI examination, together with the image processing and histopathological
correlation studies has been conducted to detect hypoxic atherosclerosis in animal and human
subjects. The specific aims for this work are as follows:
Specific Aim 1: Radiolabeling of 64Cu-ATSM compounds
I practiced the steps of processes to radiolabel of

64

Cu with ATSM compounds using in-house

methods for future pre-clinical and clinical studies.
Specific Aim 2: Evaluating the capability of

64

Cu-ATSM PET imaging for determining

hypoxia in atherosclerotic plaque.
I first demonstrated the feasibility of 64Cu-ATSM for the identification of hypoxic atherosclerotic
plaque and evaluate the relative effects of diet and genetics on hypoxia progression in
atherosclerotic plaque in a genetically-altered mouse model. We then fully validated the feasibility
of using

64

Cu-ATSM to image the extent of hypoxia in a rabbit model of atherosclerotic-like

plaques using a simultaneous PET-MR system. Finally, we proceeded with a pilot clinical trial to
determine whether

64

Cu-ATSM MR/PET scanning is capable of detecting hypoxic carotid

atherosclerosis in human subjects.

4

Specific Aim 3: Improving

64

Cu-ATSM PET image quality via corrections for partial

volume effects and photon attention effects.
I improved the

64

Cu-ATSM PET image quality though: (1) reconstructing the PET image using

Siemens HD (high-definition) PET software incorporating our optimized reconstruction
parameters; (2) investigating 4 partial volume effects (PVE) correction methods using phantom
and clinical data; (3) incorporating attenuation effects of the carotid surface coil in the MR
attenuation correction (AC) μ-map for PET image reconstruction.
This dissertation represents a development of

64

Cu-ATSM as a hypoxic atherosclerotic plaque

imaging agent to identify carotid atherosclerotic plaque clinically. Correction for spillover/partial
volume effects and photon attenuation effects were investigated to improve the PET image quality.
Correlation between the 64Cu-ATSM uptake with atherosclerotic parameter measured by MRI and
immunohistochemistry staining solidly confirmed the finding of atherosclerosis and validated the
potency of 64Cu-ATSM to identify carotid atherosclerosis in patients.

5

Chapter 2: 64Cu-ATSM-PET imaging of
hypoxia in atherosclerosis
Using 64Cu-ATSM to target hypoxic cells within plaque is of interest to us because this imaging
radiopharmaceutical has been used extensively in preclinical models and human subjects to assess
tumor hypoxia in oncology but its use in cardiology has so far been limited to assessing myocardial
ischemia (11, 27-29). However, there is growing evidence that the combination of increased
oxygen demand together with impaired oxygen diffusion capacity also results in the presence of
severe hypoxia (<1% oxygen) in macrophage-rich zones into the lesion (26, 30-32).

2.1 Atherosclerosis: a dangerous chronic cardiovascular
disease
The development of atherosclerosis in individuals with hyperlipidaemia and signs of systemic
inflammation is initiated by the activation and dysfunction of endothelial cells (33). This local
endothelial-cell defect promotes the adhesion of leukocytes and activated platelets to the damaged
endothelium and leads to an increase in the permeability of blood vessels for lipid components in
the plasma, such as low-density lipoprotein (LDL). Monocytes, which become loaded with cellactivating oxidized LDL (oxLDL) and other lipids, then accumulate in the evolving lesion and
transform into foam cells to form early plaques (known as fatty streaks) in the intima. The intima
then becomes thicker as a result of a pathophysiological response to changes in fluid dynamics at
atherosclerosis-prone areas of the arterial tree, such as artery branching points. Fatty streaks
progress into advanced atherosclerotic plaques following the accumulation of additional
inflammatory-cell subsets and extracellular lipids to form a core region that is surrounded by a cap
of smooth muscle cells (SMCs) and a collagen-rich matrix. The secretion of cytokines and growth
factors by plaque cells, and the further deposition of extracellular matrix components, contribute
6

to the progression of plaques that cause a narrowing of the arterial lumen (stenosis). The central
core of the mature plaques can become necrotic, and neovascularization in the plaques can allow
leakage of blood components and haemorrhage (33) (Fig. 1).

Figure 1 The progression of atherosclerotic lesions. a). Endothelial-cells become dysfunctional and are activated by
hyperlipidemia which leads to a pro-inflammatory state, early platelet and leukocyte adhesion, and increased
endothelial permeability. b). In early lesions, monocytes are recruited to the intima and subintima. These monocytes
scavange lipids and, thus, turn into macrophages (foam cells). Grossly, this appears as fatty streaks along the intima
of the artery wall. Monocytes continue to enter, and matrix components and vascular smooth muscle cells cause plaque
fibroproliferative progression. c). In advanced lesions, hypoxia and apoptosis of macrophages causes a necrotic core.
A fibrous cap develops. When a plaque is hypoxic, neovascularization can develop. This often begins in the adventitia.
Disruption of the neoangiogenesis can lead to plaque hemorrhage and rupture. d). Ruptured plaque often occurs after
thinning and erosion of the fibrous cap, causing instability. This often leads to arterial occlusion causing myocardial
infarction or stroke. (33, 34) (Adapted from “The multifaceted contributions of leukocyte subsets to atherosclerosis:
lessons from mouse models,” by Christian Weber, Alma Zernecke and Peter Libby, 2008, Nature Reviews
Immunology, Volume 8, p802-815. Copyright (2008) by title of publisher.)
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The atherosclerotic lesions, or atherosclerotic plaques, are roughly separated into two broad
categories: stable and unstable (also called vulnerable) (35). In general, stable atherosclerotic
plaques are rich in extracellular matrix and smooth muscle cells, and tend to be asymptomatic. On
the other hand, unstable plaques are characterized by weak and rupture-prone extracellular matrix
separating the lesion from the arterial lumen (also known as the fibrous cap), rich macrophages
and foam cells, large lipid-rich necrotic core, increased plaque inflammation, positive vascular
remodeling, increased vasa-vasorum neovascularization, and intraplaque hemorrhage (36, 37).
Ruptures of the fibrous cap expose thrombogenic material, such as collagen, to the circulation and
eventually induce thrombus formation in the lumen. Upon formation, intraluminal thrombi can
occlude arteries outright (e.g., coronary occlusion), but more often they detach, move into the
circulation, and eventually occlude smaller downstream branches causing thromboembolism (e.g.
coronary thrombosis causing myocardial infraction) (38). Apart from thromboembolism,
chronically expanding atherosclerotic lesions can cause complete closure of the lumen.
Chronically expanding lesions are often asymptomatic until lumen stenosis is so severe (usually
over 80%) that blood supply to downstream tissue(s) is insufficient, resulting in ischemia (38, 39).
Atherosclerotic plaque is dangerous because it's so “stealthy”. This process of narrowing and
hardening of the arteries occurs over decades, usually without any symptoms (40). It affects the
entire artery tree, but mostly larger, high-pressure vessels such as the coronary, renal, femoral,
cerebral, and carotid arteries (39). However, because early and intermediate atherosclerotic lesions
of atherosclerosis is “clinically silent” (41), the person may notice the problem and not seek
medical until advanced lesions have ruptured to cause infraction, or when they do, physicians do
not recognize what has happened. It is thus essential to identify the vulnerable atherosclerosis in
the arteries before the life-threatening catastrophic events take place.
8

2.2 Hypoxia in atherosclerotic lesions
It has been demonstrated that atherosclerotic lesions, in particular macrophage-rich areas in
advanced plaques which are more vulnerable, contain regions of severe hypoxia (26, 31).
Recent studies have shown that hypoxia is involved in several processes that contribute to the
progression of atherosclerotic lesions (Fig. 2). In the initial stages of atherogenesis, modified
lipoproteins recruit monocytes and T cells into the intima (42). Recruited monocytes differentiate
into macrophages and internalize the modified lipoproteins, resulting in the accumulation of highly
oxygen-consuming lipid-loaded macrophages (also known as foam cells) in developing lesions
before cell apoptosis (43). The intima and media of the artery wall rely on oxygen supplied from
the luminal blood and the adventitial vasa vasorum, and the maximum oxygen diffusion limit (100200 μm) is often exceeded in developing lesions (44). Thus, the combination of increased oxygen
demand together with insufficient oxygen supply results in the presence of severe hypoxia (<1%
oxygen) in macrophage-rich zones 150-300 μm into the lesion (26, 31).
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Figure 2 Hypoxia promotes the formation of highly oxygen-consuming, lipid-loaded foam cells. Exposure of
macrophages to hypoxia resultes in chemokine secretion which promotes recruitment of monocytes and T cells to
induce an inflammatory response, and increased lactate and decreased ATP levels in hypoxic macrophages which
promote progression of advanced lesions, and increased LDL oxidation which further promotes formation of foam
cells. (Adapted from “The role of hypoxia in atherosclerosis,” by Hultén, Lillemor Mattsson and Levin, Max,
2009, Current Opinion in Lipidology, Volume 20(5), p 409-414. Copyright (2009) by title of publisher.)

Lesion hypoxia thus may be a key factor in the progression to advanced atherosclerosis by
promoting lipid accumulation, inflammation, ATP depletion and angiogenesis.
First, hypoxia promotes formation of foam cells. Foam cells are characteristic of both early and
late atherosclerotic lesions (45, 46), and hypoxia converts human macrophages to into triglycerideloaded foam cells (47). It has been demonstrated that exposure of human macrophages to hypoxia
increases the accumulation of triglyceride-containing cytosolic lipid droplets and differentiationrelated protein (ADRP) expression, even in the absence of exogenous lipids (47).
Second, hypoxia promotes inflammation. Hypoxia has been shown to influence gene expression
in macrophages, leading to an inflammatory response with increased production of the T cell
attractant IL-8/CXCL8 (48). Hypoxia-induced chemokine secretion from macrophages leads to
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the recruitment of T cells and monocytes to atherosclerotic plaques and, subsequently, to plaque
progression (49). Additionally, the hypoxia-induced activation of macrophages plays a role in the
production of reactive oxygen species and subsequent lipoprotein modification (48, 50).
Third, hypoxia induces ATP depletion. The most central role of oxygen is to maintain
mitochondrial ATP production. Macrophages maintain ATP levels in a 100-200 μm rim of the
hypoxic zone of advanced lesions, which is the rim closest to the lumen (51). This is not surprising
because macrophages efficiently adapt to hypoxia by producing ATP from anaerobic glycolysis
(51). Glycolysis, however, is energy-inefficient and consumes 15 times more glucose per ATP
molecule produced than mitochondrial ATP production. To satisfy the high glucose demand, there
is an upregulation of the hypoxia-inducible transcription factor (HIF)-1α-regulated glucose
transporter GLUT-3 in hypoxic macrophages (26). The extensive glycolysis also promotes lactate
accumulation with the lesion, which results in decreased pH and increased binding of native and
modified lipoprotein to human proteoglycans, a mechanism that may enhance lipoprotein retention
and lipid accumulation in the atherosclerotic lesion (52, 53). Deeper into the lesion, macrophage
ATP production fails because anaerobic glycolysis decreases glucose concentrations. Importantly,
ATP-depleted macrophages in this zone remain viable and may be further depleted in lipid-loaded
macrophages by the hydrolysis and re-esterification of LDL cholesterol esters in a futile ATPconsuming cycle (51, 54). ATP depletion is likely a key factor promoting macrophage death and
the formation of necrotic core, a key feature of an unstable lesion and consisted largely of dead
macrophages, probably in concert with toxic stimuli such as free cholesterol loading and
endoplasmatic stress (51).
Moreover, hypoxia induces lesion angiogenesis. A recent study in human atherosclerotic lesions
showed a strong correlation between hypoxia and angiogenesis (26). It is likely that angiogenesis
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is promoted within plaques in an attempt to restore tissue oxygenation and ATP level (55).
However, lesion angiogenesis may be maladaptive as it not only fails to restore oxygenation but
also promotes lesion instability (44). One explanation is that lesion angiogenesis is a sign of more
hypoxic lesions, and thus more advanced atherosclerosis (26, 56). There is also evidence that lesion
angiogenesis per se may be detrimental. In mice models, angiogenic vessels provide an additional
route for inflammatory cells to enter the plaque and thus promote atherosclerosis progression (57,
58). In human lesions, angiogenic vessels are structurally defective, showing features typical of
vascular endothelial growth factor (VEGF)-induced angiogenic vessels (59). Angiogenic vessels
formed under the influence of this HIF-1-regulated angiogenic factor are characterized by poorly
supported walls, leakiness, and blind-ending vessel tubes, which make perfusion sluggish and
oxygen delivery inefficient (60). Angiogenesis has been shown to correlate with VEGF in human
atherosclerotic lesions (26), and thus hypoxia-induced increases in VEGF may contribute to the
development of unstable lesions by promoting angiogenesis.
In conclusion, in spite that additional studies are required to understand the precise mechanisms
involved in the many responses to hypoxia in the process of atherogenesis, the level of hypoxia
has pronounced effects on almost every aspect of cell physiology (61). In particular, our focus was
on the role of hypoxia on the formation of lipid-loaded macrophages and increased inflammation.
These two responses may be inter-related as recent evidence has shown that lipid droplets are
dynamic organelles with many enzymes involved in inflammation located on their surface.

2.3 PET imaging of hypoxia
In recent decades there has been increasing interest in developing methods for measuring the levels
of oxygen in tumors, which can probably be expanded to other human tissues such as
atherosclerotic plaques. The existing techniques for in vivo evaluation tissue hypoxia status was
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summarized in (62).These methods can be separated into three major groups: methods directly
related to assessing the oxygen concentration (e.g. oxygen electrodes/optodes, phosphorescence
quenching, photoacoustic lifetime imaging, electron paramagnetic resonance (EPR), overhauserenhanced MRI), methods reporting on the physiologic processes involving oxygen molecules (e.g.
detection of metabolized exogenous markers PET and PIMO, near-infrared spectroscopy (NIRS),
blood oxygen level-dependent (BOLD) MRI, dynamic contrast-enhanced (DCE) MRI,
photoacoustic tomography), and methods evaluating the expression of endogenous markers as a
response to hypoxia (e.g. CAIX, HIF-1α, GLUT-1, OPN, LOX, Ephrin A1, Galectin 1) (62).
These methods can be invasive, such as the polarographic O2 sensor (Eppendorf GmbH, Hamburg,
Germany), or non-invasive, mainly based on imaging techniques (63, 64). Non-invasive imaging
modalities are undoubtedly more appealing for the assessment of tissue hypoxia because they
guarantee all-encompassing visualization and can identify the phenomenon even at sites
inaccessible to invasive procedures. Among the many techniques now available are optical-based
methods, magnetic resonance imaging (MRI), and nuclear medicine techniques (64-66). Among
the potential image-based modalities for hypoxia assessment, positron emission tomography
(PET) is one of the most extensively investigated based on the various advantages it offers: (a) a
broad assortment of radiopharmaceuticals; (b) reasonable intrinsic resolution (~4 mm); (c) threedimensional (3D) tissue representation; (d) possibility of semiquantification/quantification of the
hypoxic burden; (e) relative ease of use, and (f) ease of repetition (67). Compared with the other
non-invasive techniques, however, the biggest advantage of PET is that it using certain radiotracers
such as 64Cu-ATSM it displays the highest specificity for hypoxic tissue (68).
Starting with the 2-nitroimidazole family of compounds in the early 1980s (66, 69), a great number
of PET tracers have been developed for the identification of hypoxia in living tissues and solid
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tumors (Fig. 3; also see Table 2 in (64) for details). The driving force behind this development has
been the need for highly specific imaging “probes” able to overcome the inconsistent correlation
between findings on other imaging modalities, including PET with18F-fluorodeoxyglucose (18FFDG), and the hypoxia levels determined in tumor tissue (66, 70, 71).

Figure 3 Structure of representative hypoxia PET imaging agents. (Adapted from “Positron Emission Tomography
Imaging of Hypoxia,” by Suzanne E. Lapi, Thomas F. Voller and Michael J. Welch, 2009, PET Clin, Volume 4
(1), p39-47. Copyright (2009) by title of publisher.)

As an FDA approved radiopharmaceutical, 18F-FDG is widely available and remains a cornerstone
for the assessment of glucose metabolism in heart, lungs, brain, and tumors in oncology, but it
requires careful handling when trying to depict hypoxic tissue (71). Patient studies by Folco el al.
concluded that glucose uptake and therefore FDG uptake signals in atheroma may reflect hypoxiastimulated macrophages rather than mere inflammatory burden, which suggested that PET imaging
using

18

F-FDG could detect “active” atherosclerotic plaques (72). The fact that tumor

hyperglycolysis due to up-regulation of glucose transporters (GLUTs) and glycolytic enzymes can
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be can be driven by HIF-1α offers some justification for the use of 18F-FDG as a surrogate marker
of hypoxia (69, 71, 73) (Fig. 4A). Moreover, under reduced oxygen level (↓pO2), living cells
switch their metabolic pathway for ATP production to anaerobic glycolysis, also known as the
Pasteur effect (74). In the case of hypoxic tumor cells, a wide overlap exists between 18F-FDG
uptake due to aerobic glycolysis, the so-called Warburg effect (75), and anaerobic glycolysis (74,
76) (i.e., normoxic and hypoxic conditions, respectively) (Fig. 4A). The fact that HIF-1α
expression can be observed also in non-hypoxic tumor regions (77, 78) suggests that other factors
can indirectly influence glucose metabolism and 18F-FDG uptake in those areas (71). This limits
on the specific application of 18F-FDG for the detection of hypoxia in tumor and probably
atherosclerosis.
Several radionuclide-labeled hypoxia markers have been developed for PET – for example, 2nitroimidazole-containing agents that rely on the reduction of nitro function groups in hypoxia
conditions and then covalent binding to macromolecules in hypoxic conditions (e.g.
fluoromisonidazole (FMISO) (79),

18

F-fluoroazomycinarabinofuranoside (FAZA) (80),

18

F-

18

F-

tracer 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluororpropyl) acetamide (EF5)) (81), Cucontaining bis-(thiosemicarbazone) complexes (e.g. Cu-ATSM) that rely on the one-electron
reduction of the metal center and

99m

Tc-labeled 4,9-diaza-3,3,10,10-tetramethydodecan-2,11-

dione dioxime (99mTc-HL91) that relies the bioreducible property of

99m

Tc itself and has been used

as markers of myocardial hypoxia (82). Silvola et al. introduced 18F-EF5 for its ability of detecting
hypoxia in atherosclerotic plaques in mice (17). EF5 has been used to detect hypoxia in rodent and
human tumors, and it has shown good correlation with other hypoxia markers, such as HIF-1. The
study included 2 types of atherosclerotic mice with different genetic backgrounds (low-density
lipoprotein receptor-/- apolipoprotein B100/100 and insulin-like growth factor II/ low-density
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lipoprotein receptor-/- apolipoprotein B100/100). After dietary induction of plaque development,
both types of mice and control mice were injected with 18F-EF5. Large atherosclerotic plaques in
mice contained hypoxic areas and showed uptake of
despite its slow blood clearance, the high uptake of

18

18

F-EF5. Their study demonstrated that

F-EF5 in plaques suggested that plaque

hypoxia is a potential target for identifying high-risk plaques noninvasively.
Among all the hypoxia PET imaging agents,

18

F-fluoromisonidazole (18F-FMISO) has received

most attention (66). 18F-labeled misonidazole was first proposed as a radioactive derivative of the
nitroimidazoles (83, 84). Like the other compounds in the nitroimidazole family, this tracer is
passively diffused through the cell membrane owing to its lipophilicity, and once within the
intracellular environment it is reduced into R-NO2 radicals by the nitroreductase enzyme (NTR).
This process is reversible and when the cell is well oxygenated, the tracer is not entrapped and can
freely flow back into the extracellular environment. Conversely, in the presence of reduced levels
of oxygen (pO2 <10 mmHg) the process of 18F-FMISO reduction continues slowly; the
consequence is the progressive production of R-NHOH compounds that bind covalently to
intracellular molecules, and ultimately entrapment of the tracer within the cell (16, 85, 86) (Fig.
4B).
Over the past two decades 18F-FMISO has been extensively studied as a PET agent for imaging
hypoxia in both the preclinical and the clinical context and to date (66). It has been shown to be
retained in hypoxic cells both in vivo and in vitro. 18F-FMISO has been used in numerous oncology
clinical studies including gliomas (87), head and neck cancer, and non-small cell lung cancer (88).
In an early study involving patient with malignant glioma, a feasibility study demonstrated the use
of FMISO to detect hypoxia in the brain in vivo (89). 18F-FMISO is currently the most widely used
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PET agent for mapping regional hypoxia and is generally considered to be the gold standard for
PET hypoxia imaging (66).
Nevertheless, the aspects representing the main drawbacks of

18

F-FMISO may limit the

applicability of the tracer in clinical practice. Owing to the high lipophilicity and slow kinetics of
this tracer, 2-4 h post intravenous injection imaging times are required which is rather long for
an 18F-fluorine labeled tracer (T1/2 = 109 min) (90, 91). In addition, high contrast images are not
typical with this agent (tumor-to-plasma or tumor-to-muscle ratio of 1.2-1.4 (66, 90) ). The slow
washout of this tracer leading to a delay time of two hours required after injection to allow for
clearance of the tracer from normal background tissues delays imaging and can result in poor
statistics and images of limited quality (92).
[64Cu]Copper(II)-diacetyl-bis(N4-methylthiosemicarbazone

(64Cu-ATSM)

(Fig.

4C)

was

developed as an alternative to 18F-FMISO (66). [64Cu] (t1/2 = 12.7 h, β+ = 17.4%) can be produced
in high specific activity in reliable quantities and the longer half-life allows for distribution to
centers without a cyclotron over longer distances than possible with 18F (66). This isotope also
decays by β− and can therefore have potential as both a diagnostic and therapeutic agent (9).
Section 2.4 will introduce the properties of 64Cu-ATSM in more detail.
In the assessment of tumor hypoxia,

64

Cu-ATSM overcomes many limitations of

18

F-FMISO.

64

Cu-ATSM is an agent that shows rapid delineation of tumor hypoxia (<1 h), and in high tumor

to background tissue ratios (tumor-to-blood ratio >>2.0) which allows prediction of poor response
to therapy (93). In addition, Cu-ATSM shows higher and faster cellular uptake than FMISO in
vitro, and correlated with O2 electrode studies (93). The more efficient uptake and washout kinetics
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of 64Cu-ATSM in hypoxic and normoxic cells compared to 18F-FMISO offers the possibility of a
faster and more selective means of detecting hypoxia by PET imaging.
All of these hypoxia agents have shown certain preferential uptake in hypoxic cells, although
thorough validation studies are still needed for them to be used with confidence clinically.

Figure 4 Comparison of the retention mechanisms of (A) FDG, (B) F-MISO (B), and (C) Cu-ATSM (C) in hypoxic
living cells. The cellular uptake of FDG occurs both in normoxic (Warburg effect) and hypoxic conditions (Pasteur
effect), while the retention of F-MISO and Cu-ATSM after passive diffusion through the cell membrane depends on
oxygen tension (pO2) of the cells. In the condition of reduced pO2 (hypoxia), F-MISO is progressively reduced by
nitroreductase enzyme (NTR) and covalently bound to the intracellular proteins; Cu(II)-ATSM nuclide is reduced to
Cu(I) by the intracellular thiols, and less stable Cu(I)-ATSM complex is progressively dissociated to form H2-ATSM
and free Cu(I), which is very rapidly incorporated into intracellular proteins. In the presence of sufficient O 2
(normoixa) the processes are reversible and the F-MISO and Cu(II)-ATSM molecules are free to leave the cell.
(Adapted from “PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence," by Egesta Lopci
et al., 2014, Am J Nucl Med Mol Imaging, Volume 4(4), p 365-384. Copyright (2014) by the title of publisher and is
released under the “Creative Commons Attribution Noncommercial License (CC BY-NC) License.)

2.4 Cu-ATSM as a hypoxia imaging agent for PET
Cu-ATSM is a promising hypoxia marker in PET imaging with a lot of advantages. The
radiolabeling of Cu-ATSM is relatively easy with a 1-step reaction between copper and the
substrate. Cu-ATSM has small molecular weight and is a neutral lipophilic molecule and highly
membrane permeable; thus, it can diffuse easily from bloodstream to surrounding cells.
The bis(thiosemicarbazone) ligands in Cu-diacetyl-bis (N4-methylthiosemicarbazone) [CuATSM] derived from 1,2-diones react rapidly with copper to form stable, low molecular weight,
neutral complexes which are capable of fast cellular uptake. For thiosemicarbazone complexes,
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the reductive potential can be altered to match the bioreductive character of the oxygen-depleted
tissue by modifying the chelate. Cu-ATSM depends on its single methyl group, which shifts its
Cu(II/I) redox potential by approximately 80 mV. In contrast, the blood perfusion agent

64

Cu-

pyruvaldehyde-bis(N4-methylthiosemicarbazone) [PTSM] is not hypoxia selective. This change in
chemical property is hypothesized to be due to subtle energy shifts in the frontier orbitals that alter
the order and, as a consequence, the occupancy of these orbitals (94).
Copper has several positron-emitting isotopes (60Cu, 61Cu, 62Cu, and 64Cu) with various half-lives,
ranging from 9.7 minutes for 62Cu to 12.7 hours for 64Cu. This allows a wide choice of isotopes,
so that half-life (t1/2) and radiation energy level can be tailored to particular needs. 60Cu (t1/2 = 23.7
min), 61Cu (t1/2 = 3.35 h), and 64Cu (t1/2 = 12.7 h) can be produced by proton bombardment of solid
targets using a medical cyclotron, while 62Cu is available from a generator similar to that used
for 99mTc (66, 93). Among them, Copper-64 is the most commonly used copper isotope (93). It has
been reported in that 64Ni(p, n)64Cu nuclear reaction can produce large quantities of the nuclide
with high specific activity (95). The 12.7-hour half-life of

64

Cu makes it ideally suited for PET

studies that can be conducted over a 48-hour period, while the short half-lives of 60Cu and 62Cu
preclude delayed imaging. This long half-life also allows for the regional distribution of this
nuclide, as with 18F. Copper-64 decays 17.4% by positron emission and has a β+ maximum energy
of 0.66 MeV, similar to 18F, with an average energy of 0.28 MeV. This low kinetic energy positron
results in short positron range (2.4 mm Rmax and 0.6 mm Rmean) and therefore high resolution PET
images (96, 97). Copper-64 also decays by electron capture (43%) and β- (43%) and has, therefore,
been studied as both a diagnostic and therapeutic radionuclide (9).
The first report of the hypoxia selectivity of Cu-ATSM was with 62Cu-ATSM in an isolated rat
heart model of ischemia in 1997 by Takahashi and colleagues (28), and the first report of Cu19

ATSM in human study was conducted in normal subjects and patients with lung cancer by the
same group (98). Because of the profound impact of hypoxia on tumor behavior (99),

64

Cu-

ATSM has also been extensively studied subsequently by Michael Welch, Farrokh Dehdashti,
Jason Lewis and colleagues in Washington University in St. Louis for noninvasive detection and
quantification of tumor hypoxia in vitro (12, 100) and in vivo (13, 14, 101).
The retention mechanism of

64

Cu-ATSM in viable cells under low cellular partial pressure of

oxygen (PO2) explored by a number of groups in the US, Europe and Japan over the last few
decades. Although different schemas in the retention mechanism of Cu-ATSM were proposed in
the literature, but, to date, there is a consensus that in vitro Cu-ATSM undergoes bioreductive
trapping under hypoxic conditions (11, 102-104). As presented by Fujiyabashi et al. (11, 27), in
theory Cu-ATSM Cu(II) is a lipophilic molecule, with high membrane permeability and low redox
potential, and is reduced only in hypoxic cells and involves electron transfer from hyper-reduced
Complex I (ubiquinone oxidoreductase) using NADH as a two-electron donor. Upon the
intracellular reduction, Cu-ATSM becomes trapped irreversibly and thus the radioactivity
accumulates in these areas. In normoxic cells, Complex I is incapable of reducing Cu-ATSM (Fig.
4C).
It has been shown that redox potential is the major factor controlling hypoxia selectivity but not
the only one: although complexes with potentials in the range -0.57V to -0.59V were all hypoxia
selective, they differed in the degree of selectivity (102). Varying the alkylation pattern of bisthiosemicarbazone complexes or substituting sulfur with selenium as the donor atom can change
the properties of the thiosemicarbazone complexes. McQuade examined new copper hypoxia PET
imaging agents for a higher selectivity for hypoxia or ischemic tissue by increasing alkylation or
replacing the sulfur atoms with selenium (94). Of the compounds synthesized, only 64Cu-ASSM
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(2,3-butanedione

bis(-selenosemicarbazone))

and

64

Cu-ATSE

(diacetyl-bis(N4-

ethylthiosemicarbazone)) could be examined in vitro and in vivo. The additional alkylation present
in Cu-ATSE modifies the hypoxia selectivity and in vivo properties when compared with CuATSM. However, the fully alkylated species,

64

Cu-ASSM demonstrated no hypoxia selectivity

(94).
It should be noted that 64Cu-ATSM has been shown to be a valid PET hypoxia marker in some
tumor types, but not for all (18). Although all types of solid tumors, especially malignant solid
tumors, are subject to hypoxia, the oxygen tension in tumors and fraction of hypoxic tumors are
significantly varied (also see Table 1 in (62)). This cell–dependent hypoxia selectivity of 64CuATSM, along with its time-dependent spatial distribution and retention kinetics suggested in other
studies, raises concerns regarding the usage of

64

Cu-ATSM as a universal PET hypoxia marker

(18-23) . Therefore, further studies are needed to validate the retention behavior for this PET
marker in hypoxic atherosclerotic plaques.

2.5 Preparation the compound of 64Cu-ATSM
Preparation the compound of 64Cu-ATSM was clearly divided into two major components: 64Cu
isotope production and radio-labelling of

64

Cu-ATSM. The

64

Cu isotope was produced on the

Washington University CS-15 cyclotron by the ⁶⁴N (p,n)⁶⁴Cu nuclear reaction as previously
described (95, 105).

2.5.1 Preparation of 64Cu-ATSM doses for preclinical studies
Radioactivity was counted with a Beckman Gamma 8000 counter containing a NaI crystal
(Beckman Instruments, Inc., Irvine, CA). EM Science Silica Gel 60 F254 thick-layer
chromatography (TLC) plates (10 × 5 cm) were purchased from EMD Millipore Corporation
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(Billerica, MA). Radio-TLC plates were analyzed using a BIOSCAN System 200 imaging scanner
(Bioscan, Inc., Washington, DC).
Diacetyl-bis (N4-methylthiosemicarbazonate) [H2-ATSM] was labeled with

64

Cu using the

methods developed in house. Briefly, 10 mg of ATSM powder was dissolved in 1 ml of DMSO to
give an overall concentration of 10 mg/mL. A total of 1 µL (10 µg) of this solution was then added
to 1 µL (~92.5 MBq) of 64CuCl2 in 200 µl of 1 M NaOAc or 3 M HCl buffer, at a concentration of
0.46 MBq/µL. This solution was then stirred for 3 to 5 minutes and then allowed to sit briefly at
room temperature, after which it was loaded onto a C18 Sep-Pak® Light (Waters Corporation,
Milford, MA), which had been pre-conditioned with 5 mL of ethanol and 5 mL of water. After
loading the sample, 10 mL of water was passed through to remove the DMSO and any unreacted
64

Cu. The labeled complex was then eluted in 350 µL of ethanol (following a 150 µL ethanol

elution for the void volume). The purity of the labeled material was determined by radio-TLC
using silica gel plates with ethyl acetate as the mobile phase. Radiochemical yield was 75-85%
and purity > 95% (Fig 5).
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Figure 5 Demonstration of the materials for preparing 64Cu-ATSM pre-clinical doses.

2.5.2 Preparation of 64Cu-ATSM doses for clinical studies
Preparing 64Cu-ATSM compounds for patient studies was more rigorous than for animal studies.
During all procedures, personnel must follow all good manufacturing practice (GMP) rules in
addition to all radiation safety procedures at the drug compounding site: lab coats, eye protection
and disposable protective shoe covers were needed; sleeve protectors and two pairs of disposable
gloves must be worn; all personnel must wear TLD radiation badges and rings.
I.

Drug Compounding Environment

For ATSM preparation, drug compounding took place in an ISO Class 5 environment and involved
aseptic processing. Principles of ALARA were observed for all aspects of drug compounding.
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II.

Supplies and Equipment

Supplies used to produce ATSM included lyophilized ATSM ligand (50-mL vial from PTI, Inc.),
ATSM reconstitution solution (10-mL vial from PTI, Inc.),

64

CuCl2 in 0.1 M HCl (10-mL

evacuated vial), radiation shield for vial of 64CuCl2 solution, and 6” extension tube (Fig. 6A).
Additional supplies were three 0.22-µm Millex-GV sterile filters, two 10-mL Luer-Lok syringes,
one 60-mL Luer-Lok syringe, five 21-gauge needles, one 19-gauge 3 ½-inch spinal needle, one
33” extension tube, one 10-mL sterile evacuated vial, six sterile 70% isopropyl alcohol pads (Fig.
6B).
The equipment required were freezer for storage of Lyophilized ATSM kit, refrigerator for storage
of reconstitution solution, tongs, dose calibrator, vortex mixer, and radiation shield for final
product vial.
III.

Procedures of 64Cu-ATSM synthesis

First, we reconstituted the ATSM ligand in the lyophilized ATSM vial and the reconstitution
solution. Second, ATSM was radio-labelled with 64CuCl2. Then, we placed a 10-mL sterile empty
vial into a radiation shield to prepare the product vial, and prepare and insert two 21-gauge needleMillex GV filter assemblies into the septum of the Product Vial as depicted (one high, one low)
(Fig. 6C). We attached a 33” extension tube to the upper needle-filter assembly on the product
vial, attached a 60-mL syringe to the 33” tube, and attached a 6” extension tube to the lower. We
inserted the spinal needle as well as the vent filter into reaction vial (Fig. 6D).
The last step was sterile filtration of drug product. We slowly drew back on the 60-mL syringe
connected to the 33” extension tube; the reaction solution was pulled through the sterilizing filter
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into the product vial (Fig. 6E). Complete fluid transfer from the Reaction Vial was visually
checked. When the fluid transfer was complete, we withdrew the needle-filter assemblies from the
product vial.

Figure 6 Preparation of 64Cu-ATSM patient doses. A). Supplies for 64Cu-ATSM synthesis; B). Additional supplies
for 64Cu-ATSM synthesis; C). Preparation of product vial; D). Preparation of reaction vial; E). Sterile filtration of
drug product. (Courtesy of Tom Voller, WUSM)

IV.

Membrane Integrity Test

After the ATSM preparation, the Millex-GV Sterilizing Filter was removed from the 6” tube to
perform membrane integrity testing according to institutional procedures. The membrane must
pass integrity testing for drug product release. We documented the results of radiopharmaceutical
compounding on the trial-specific batch record form (BR Form).
V.

Radiochemical Purity Test

The Oasis cartridge was used for radiochemical purity test. When the 64Cu-ATSM sample and
Oasis cartridge were prepared, the sample was loaded onto the cartridge, rinsed on cartridge with
1 ml of 0.9% NaCl two times, and eluted by washing the cartridge with 1 ml of absolute ethanol
three times (Fig. 7). Lastly, the cartridge was removed for assay. Radiochemical Purity (RCP) was
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then calculated. The RCP must be > 95%, and the results of radiopharmaceutical purity testing
was documented on the trial-specific batch record.

Figure 7 Setting up of Oasis Cartridge and Luer-Luer Transfer Set for radiochemical purity (RCP) test. (Courtesy of
Tom Voller, WUSM)
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Chapter 3: Evaluating the capability of 64CuATSM PET imaging for determining hypoxia
in atherosclerotic plaque
3.1 64Cu-ATSM small animal PET imaging of hypoxic
atherosclerosis in an ApoE-/- mouse model
This research was originally published as “Imaging of hypoxia in mouse atherosclerotic plaques
with 64Cu-ATSM” in Nuclear Medicine and Biology (106). Copyright (2016) by Elsevier Inc.

3.1.1

64

Cu-ATSM mouse study: introduction

In this study, we assessed the feasibility of imaging the development of hypoxia in an
apolipoprotein E knockout (ApoE KO or ApoE-/-) mouse model of atherosclerosis using the PET
imaging agent

64

Cu-ATSM. Lack of ApoE results in severe hypercholesterolemia and

spontaneously developed atherosclerotic lesions. This mouse model was widely used to study
atherosclerosis (107, 108), therefore we investigated the feasibility of

64

Cu-ATSM for the

identification of hypoxic and potentially unstable atherosclerotic plaque with this mouse model.
We used the hypoxia-specific dye pimonidazole and the pan macrophage marker CD68 to assess
for co-localization of hypoxia in macrophages. Pimonidazole is reduced in cells with low oxygen
tension to form protein adducts that can be detected by immunostaining (24). We hypothesized
that there would be high PET image contrast between hypoxic and normoxic tissues after the
administration of

Cu-ATSM, and that the presence of hypoxia by

64

64

Cu-ATSM uptake would

correlate with pimonidazole uptake within the ex vivo atherosclerotic arch specimens. We also
hypothesized that pimonidazole uptake would co-localize to macrophages (CD68) on
immunohistochemistry (IHC).
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3.1.2

64

Cu-ATSM mouse study: materials and methods

I. General
All animal studies were performed under a protocol approved by the Animal Studies Committee
at our institution. Ten-month-old wild type (C57Bl/6, n=7) mice weighting ~30g were purchased
from Charles River Laboratories (Wilmington, MA) and fed standard-chow diet (SCD). One-yearold ApoE-/- mice (n=9) spontaneously expressing atherosclerosis were fed SCD for one year and
had roughly the same weight as the wild type mice prior to 64Cu-ATSM PET imaging. A subset
of ApoE-/- mice (n = 4) and wild type mice (n = 4) also underwent

18

F-FDG PET imaging in

addition to 64Cu-ATSM PET imaging one day later. Additional SCD wild type mice (n = 6) and
ApoE-/- mice fed either with SCD (n = 6) or a high-fat Western type diet (n = 6; HFD, containing
21.2% fat and 0.2% cholesterol; Harlan Laboratories, Inc., Indianapolis, IN) underwent
longitudinal imaging. These mice underwent PET imaging in 2-month intervals for a total of 10
months. This was done in order to assess the uptake of

64

Cu-ATSM at various stages of plaque

development. The experimental arms are given below in Table 1. All chemicals, unless otherwise
stated, were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). Water was distilled
and then deionized (18 MΩ/cm2) by passing through a Milli-Q water filtration system (Millipore
Corp., Milford, MA).
Copper-64 ATSM doses was prepared as previously described (see section 2.4.2.1).
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Table 1 Experimental cohorts.


Preliminary Mouse Study (N = 16)
Number of Mice

Species/Diet

Age of Imaging

Radiopharmaceuticals

4

ApoE-/-, SCD

54 -62 (day 1)

9

ApoE-/-, SCD

54 -62 (day 2)

4

C57Bl/6, SCD

43 (day 1)

7

C57Bl/6, SCD

43 (day 2)

64

18

F-FDG

64

Cu-ATSM
18

F-FDG

Cu-ATSM

Longitudinal Mouse Study (N = 18)
6

ApoE-/-, HFD

14, 23, 32, 41

64

6

ApoE-/-, SCD

14, 23, 32, 41

64

6

C57Bl/6, SCD

14, 23, 32, 41

64

Cu-ATSM
Cu-ATSM
Cu-ATSM

II. Dynamic Small Animal PET Imaging
Small animal imaging studies were carried out on a Siemens Inveon (Siemens Medical Solutions
USA, Inc., Malvern, PA) or Focus 220 microPET scanner (Concorde MicroSystem Inc.,
Knoxville, TN). Isoflurane (1-2%) was used to induce and maintain anesthesia during imaging.
Each animal received ~3.7 MBq of activity in 100 µL saline via lateral tail-vein injection. Mice
were imaged in pairs in a supine position in a specially designed bed. Imaging was performed
using 0-30 minute dynamic scan sessions for 64Cu-ATSM or 0-60 minute dynamic scan sessions
for 18F-FDG. PET data was reconstructed using standard methods with the maximum a posteriori
probability (MAP) algorithm. 64Cu-ATSM images were reconstructed in 10 second intervals up to
2 minutes, 30 seconds intervals up to 5 minutes, and 5 minute intervals up to 30 minutes. 18F-FDG
scans were reconstructed in 2-5 seconds intervals up to 1 minute p.i., 10-30 seconds intervals up
to 4 minutes p.i., 60-120 second intervals up to 10 minutes p.i. and 5 minute intervals up 1 hour.
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CT was performed prior to each PET study for attenuation correction and anatomical colocalization of the PET data.
III.

Image Analysis

Images were evaluated by measuring the radioactivity concentration of the aortic arch and nontarget (thigh muscle) of each mouse on the co-registered PET/CT images using the Inveon
Research Workplace (IRW; Siemens Medical Solutions USA, Inc., Malvern, PA).
Regions of interest (ROIs) were drawn around the entire aortic arch (~15 mm3) or a region of ~50
mm3 on the thigh muscle on multiple consecutive, transaxial image slices. Time activity curves
(TACs) in kBq/cm3 were generated by plotting the ROI values over time.
Standardized Uptake Values (SUVs) were calculated by dividing the decay-corrected activity per
unit volume of tissue (Bq/cm3) by the injected activity per unit of body weight (Bq/g), as described
by the following equation:

SUV =

radioactivity concentration (

𝐵𝑞
)
𝑐𝑚3

𝐵𝑞
weight (𝑔)
body

injected dose

.

(1)

The aortic arch-to-leg muscle (A/M) SUV ratios were calculated and compared.
III.

Statistical Methods
Graph generation and statistical analysis were performed using GraphPad Prism version 6

(GraphPad Software Inc., La Jolla, CA). Differences between groups were evaluated by Student’s
t-test (two groups) or one-way ANOVA (three or more groups) using Fisher's least significant
difference method for post-hoc test. Data were reported as mean ± S.E.M. (standard error of mean)

30

unless otherwise indicated and differences at the 95% confidence level (P < 0.05) were considered
statistically significant.
IV.

Immunohistochemistry

4 mice from each subset (wild type, ApoE-/- fed SCD or HDF) were sacrificed to collect ex
vivo

endarterectomy

specimens

for

histopathological

assessment

and

pimonidazole

immunohistochemistry. The animals were injected with the hypoxia-reactive reagent PIMO
hydrochloride (HypoxyprobeTM-1 Kit, Hypoxyprobe, Inc, Belmont, MA) 60-90 minutes before
euthanasia. Specimens were embedded in paraffin and sectioned transversely. Serial 5 μm sections
of even intervals were placed on slides for immunohistochemistry and histology with hemotoxylin
and eosin (H&E) stains. Aortic arch specimens and leg muscle tissue specimens were stained for
the presence of hypoxia using an antipimonidazole antibody (Natural Pharmacia Inc., Belmont,
MA) and mounted in solution containing 4'-6-diamidino-2-phenylindole (Vector Laboratories,
Palo Alto, CA). Although PIMO may react with reactive oxygen species (109), the
antipimonidazole antibody only recognizes hypoxia derivatives (8).
Rat anti mouse CD68 antibody (AbD Serotec, Bio-Rad Laboratories, Hercules, CA) which
recognizes mouse macrosialin for the identification of CD68 was used to stain atherosclerosisassociated macrophages (110-115) in the paraffin-embedded aortic arch of mouse, and the result
was co-localized to the PIMO staining. Fluorescein isothiocyanate (116) and Cy3 fluorescent
labeled antibodies were used as the secondary fluorescent antibodies, respectively. The slides were
incubated with DAPI (4, 6-diamino-2-phenylindole) (Fluoro-Gel II with DAPI, electron
microscopy sciences, Inc., Hatfield, MA) to show cell nuclei. Negative control staining was
performed by replacing the primary antibody with matching isotype control followed by same
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fluorescent labeled secondary antibody. IHC slides were imaged by Leica TCS SP5 confocal laser
scanning microscope (Leica Microsystems Inc., Buffalo Grove, IL).
V.

Autoradiography

Specimens from 4 SCD ApoE-/- mice and 4 wild-type control mice were collected for
autoradiography. The animals were injected with pimonidazole hydrochloride 60-90 minutes
before euthanasia. Harvested fresh tissues of aortic arch (with heart attached) were fixed in 4%
Paraformaldehyde (PFA) for ~12 hours and cut transversely into a series of adjacent sections on a
cryostat (Leica) at 20 µm thickness and attached to adhesive glass slides (CFSA 1X, Leica
Microystems, Buffalo Grove, IL). Both the aortic arch of the control mice and the heart of the
same ApoE-/- mice were used as negative controls. The slides used for autoradiography were
covered by adhesive tape (CryoJane Tape Transfer System®, Leica Microsystems, GmbH,
Nussloch, Germany) and exposed to a phosphor imaging plate (GE Healthcare Life Sciences,
Pittsburgh, PA) for 12 hours at -20oC, and the plates were scanned using phosphor imager plate
scanner (Storm® 840, Amersham Biosciences Corp., Piscataway, NJ). The resulting images were
processed using ImageQuant 5.2 (Molecular Dynamics, Inc, Sunnyvale, CA) and ImageJ (v1.48,
public domain) software. After decaying for at least 3 days, the adjacent slides were treated with
pimonidazole and CD68 staining for the presence of hypoxia and macrophages. Due to the
different resolution of the immunohistochemistry image obtained from the confocal microscopy
(< 5µm) and the autoradiograph obtained from the plate scanner (50 µm), the autoradiographs
were scaled up 11.2 times with bilinear interpolation to match the size of the IHC images in the
same ROI for comparison.
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3.1.3

64

Cu-ATSM mouse study: results

64

Cu-ATSM was distributed rapidly in the blood pool and quickly excreted; thus activity was found

in the kidney and liver at all time-points post injection likely due to clearance. The leg muscle is
not hypoxic under normal conditions and therefore was used for comparison with aortic arch. A
strikingly different uptake pattern was observed between muscle and aortic arch. ROIs were drawn
on the PET and CT co-registered images over the aortic arch and an area of leg muscle on each
mouse after administration of 64Cu-ATSM or 18F-FDG (Fig. 8).

Figure 8 Representative small animal PET images from SCD ApoE -/- and wild type (control) mice. Summed images
of coronal (top) and transverse (bottom) slices 7.5-30 minutes post injection (p.i.) of 64Cu-ATSM (left) and 40-60
minutes p.i. of 18F-FDG (right) with ROIs of aortic arch (in blue circles) drawn on each mouse.

7.5 minutes post injection of 64Cu-ATSM, the radioactivity in the aortic arch and leg muscle
was stable (Figure 9A), while the difference in time activity curves (TACs) of aortic arch between
the SCD ApoE-/- mice and control mice increased over time from 15 minutes post injection of 18FFDG until the end of imaging (Figure 9B). There was no significant difference in activity in leg
muscle (background) (Figure 9, A and B). The average SUVs of the aortic arch 7.5-30 minutes
post injection of 64Cu-ATSM were significantly higher in the SCD ApoE-/- mice (n = 9) than the
wild type mice (n = 7): 7.80 ± 0.41 and 5.45 ± 0.52, respectively (p = 0.004), as were average
aortic arch to muscle (A/M) SUV ratios of the SCD ApoE-/- mice and the wild type mice: 5.66 ±
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0.23 and 3.87 ± 0.22, respectively (p < 0.0001) (Figures 10A). For the mice injected with 18F-FDG,
the A/M SUV ratios between SCD ApoE-/- mice and control mice became statistically significant
at about 40 minutes post injection of 18F-FDG (Figure 10B). The 40-60 minutes p.i. average A/M
SUV ratio difference between SCD ApoE-/- mice (n = 4, 8.07 ± 0.96) and control mice (n = 4, 4.55
± 0.21) after 18F-FDG injection (Figure 11) was also significant (p < 0.005), as was the average
A/M SUV ratio difference (5.57 ± 0.38 V.S. 3.67 ± 0.61 ) 7.5-30 minutes after 64Cu-ATSM for the
same subset of mice.

Figure 9 Time activity curves (TACs) of 64Cu-ATSM (A) and 18F-FDG (B) show increased difference in aortic arch
activity between the SCD ApoE-/- and wild type mice injected with 64Cu-ATSM in comparison to 18F-FDG injection.
Results are presented as mean ± S.E.M. in the graph. The numbers of ApoE-/- and control mice were 9 and 7 for 64CuATSM imaging, and 4 and 4 for 18F-FDG imaging, respectively.

Figure 10 A/M SUV ratios observed with small animal PET imaging after injection of 64Cu-ATSM (A) and 18F-FDG
(B) in SCD ApoE-/- mice and control mice. 64Cu-ATSM injection yields significant difference in the ratios at a faster
rate in comparison to 18F-FDG injection, which increases over time from 7.5 minutes p.i. to the end of imaging. Results
are presented as mean ± S.E.M. in the graph. The numbers of ApoE -/- and control mice were 9 and 7 for 64Cu-ATSM
imaging, and 4 and 4 for 18F-FDG imaging, respectively.
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Figure 11 Comparison of A/M SUV ratios ± S.E.M. for the same subset of SCD ApoE-/- mice (n = 4) and control mice
(n = 4) 7.5 - 30 minutes p.i. of 64Cu-ATSM and 40- 60 minutes p.i. of 18F-FDG. Significant differences were observed
between ApoE-/- mice and control mice for both 64Cu-ATSM and 18F-FDG imaging.

IHC of the aortic arch in ApoE-/- mice showed the presence of atherosclerosis whereas IHC of the
aortic arch of wild type mice did not. PIMO uptake was found in the aortic arch of both SCD and
HFD ApoE-/- mice (Fig. 12, Fig. 13). There was large overlap of the fluorescent areas
corresponding to the CD68 macrophage staining co-localized to the PIMO adducts, demonstrating
co-localization of hypoxia to macrophages (Fig. 12, Fig. 13). Wild type aortic specimens did not
demonstrate hypoxia by PIMO staining (Fig. 14). The DAPI staining for nuclei delineated and
confirmed the cellular components of the plaques imaged.
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Figure 12 Detection of PIMO adducts co-localizes with macrophages within atherosclerotic plaque of aortic arch.
Aorta were harvested from 40 week old ApoE-/- mouse on western diet for 33 week that received PIMO 2 hours prior
to sacrifice. (A) Representative image of H&E stained section from aortic arch. (B) Magnification of region of interest
from (A). (C) Immunofluorescence image from serial section of aortic arch shown in (A). Green is mAb 4.3.11.3
staining pimodiazole adducts (internal elastic lamina is autofluorescent), red is CD68 staining for macrophages, blue
is DAPI nuclear stain, and yellow is the overlay of PIMO and CD-68. Representative of at least three animals.
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Figure 13 Immunofluorescence images from serial sections of aortic arch in 10 months ApoE -/- mouse on standard
chow diet that received PIMO 2 hours prior to sacrifice. PIMO adducts were colocalized of with macrophages (CD68)
within atherosclerotic plaque of aortic arch. Green is mAb 4.3.11.3 staining PIMO adducts (internal elastic lamina is
autofluorescent), red is CD68 staining for macrophages, blue is DAPI nuclear stain. Scale bar = 100 µm.
Representative of at least three animals.
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Figure 14 Confocal laser-scanning microscopy images of the aorta harvested from 10 months old SCD wild-type
mouse that received PIMO 2 hours prior to sacrifice. No remarkable 64Cu-ATSM uptake was measured in microPET
images in the aortic arch of this mouse, which is consistent with the IHC staining that no PIMO signal was detected
in this region. (A) Representative image of autofluorescence from aortic arch (red). (B) PIMO adducts stained with
mAb 4.3.11.3 (green); internal elastic lamina is autofluorescent (C) Nuclei stained with DAPI (blue) (A). Overlay of
autofluorescence, PIMO staining and DAPI staining (117). Scale bar = 105 µm. Representative of at least three
animals.

Autoradiographs from different transverse slides confirmed that SCD ApoE-/- mice had higher
uptake of 64Cu-ATSM in comparison to the aortic arch of control mice as well as the heart of the
same ApoE-/- mice (Fig. 15A). The hot spots in the scaled-up autoradiograph (Fig. 15B) regionally
co-localized to the IHC image of the adjacent slide (Fig. 15, C-E).
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Figure 15 (A) Representative autoradiographs obtained from transverse slices of the aortic arch in SCD ApoE -/- mice
(top) and control mice (middle) and heart in SCD ApoE -/- mice (bottom) 30 minutes p.i. of 64Cu-ATSM. (B) The
section in the yellow square in (A) were scaled-up 11.2 times with bilinear interpolation. The bright spots in scaledup autoradiograph were co-localized in shape to the (C) PIMO and (D) CD-68 strongly-positive area and their merged
area. Green is mAb 4.3.11.3 staining for PIMO adducts (internal elastic lamina is autofluorescent), red is CD68
staining for macrophages, blue is DAPI nuclear stain, and yellow is the overlay of PIMO and CD68.

The results of our longitudinal studies comparing

64

Cu-ATSM uptake in SCD and HFD ApoE-/-

mice at various time points suggested that both groups of mice developed hypoxic atherosclerosis
longitudinally over time. There was no significant difference in A/M SUV ratios between the three
39

groups of mice at 14 weeks old, suggesting that no advanced atherosclerosis had been developed
in the ApoE-/- mice at that age. However, 64Cu-ATSM uptake in the both SCD and HFD fed ApoE/-

mice increased significantly from 14 to 23 weeks (p < 0.05, Fig. 16) with both SCD and HFD

ApoE-/- mice showing significantly higher A/M SUV ratios at 23 weeks (p < 0.01) in comparison
to the wild-type control mice fed with standard chow. The difference between SCD and HFD
ApoE-/- mice progressively increased over time until 32 weeks old and began to decrease until end
of the study (41 weeks old). Although HFD ApoE-/- mice always had higher A/M SUV ratios than
the SCD ApoE-/- mice, this difference was only statistically significant at 32 weeks.

Figure 16 Longitudinal study of 64Cu-ATSM uptake in ApoE-/- mice at the same age fed either with SCD or HFD.
64
Cu-ATSM uptakes were assessed by A/M SUV ratios as mean ± S.E.M of n = 6. *p < 0.01, **p < 0.001, and ***p <
0.001 are groups vs. 14 weeks groups. #p < 0.05, ##p < 0.01 and ####p < 0.0001 are SCD ApoE-/- groups vs. SCD wildtype groups at the same age. ^^p < 0.01 and ^^^^p < 0.0001 are HFD ApoE-/- groups vs. SCD wild-type groups at the
same age. +p < 0.05 is HFD ApoE-/- group vs. SCD ApoE-/- group at the same age. The numbers of ApoE-/- HFD,
ApoE-/- SCD and wild-type SCD mice were all 6.
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3.1.4

64

Cu-ATSM mouse study: discussion

This study demonstrated the utility of 64Cu-ATSM for imaging hypoxia in atherosclerotic plaque
in an ApoE-/- mouse model, permitting image contrast between hypoxic and normoxic tissues 7.530 minutes post injection. The longitudinal study investigating the role of diet and age in this
mouse model suggested that

64

Cu-ATSM imaging may assist in evaluating the progression of

hypoxia over time and formed the basis of our future preclinical and clinical studies.
It is well established that macrophages play a key role in atherosclerosis (118). In the initial stages
of atherogenesis, modified lipoproteins recruit monocytes and T cells into macrophages and
internalize the modified lipoproteins, resulting in the accumulation of highly oxygen-consuming
lipid-loaded macrophages (foam cells) in developing lesions before apoptosis (49). The present of
plaque hypoxia in macrophage-rich areas with neovascularization has been demonstrated in rabbit
advanced atherosclerosis (119). Despite relatively low resolution for autoradiography, the
brightest area in the autoradiograph, which indicated the highest

64

Cu-ATSM uptake, regionally

correlated to the PIMO and CD68 positive areas, the elevated 64Cu-ATSM was accumulated in the
hypoxic macrophage-rich core of the atherosclerotic plaques in the aortic arch of ApoE-/- mouse.
64

Cu-ATSM has time-dependent and cell-dependent spatial distribution and retention kinetics,

which result in various correlation between the uptake of Cu-ATSM and immunofluorescent
markers of hypoxia in different tumor cell lines (18-23). There are reports of mildly (pO2 < 2%
O2) (120) and severely hypoxic retention threshold (2.0-5.0 mmHg and even lower (121); 0.5%
and 0.1% O2 (12); versus 40-60 mmHg in normal tissue (122)) of 64Cu-ATSM in different tumor
types and acquisition time after injection. In a recent review article by Colombié et al. (123), the
authors attribute the low correlation between Cu-ATSM uptake and hypoxic distribution in some
tumors to the differing redox status of them. These tumor types might have a lower than average
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redox potential with high concentrations of electron donors leading to reduction and trapping of
Cu-ATSM in both hypoxic and normoxic areas, i.e. human prostate tumor which overexpresses
the fatty acid synthase (FAS) because this enzyme requires a large amount reductive species
(NADPH) as cofactor for function (123, 124). In atherosclerosis, although the redox potential
caused by ATP-consumption in the lipid-loaded macrophages does not tend to be unusually low,
we are still uncertain about the exact oxygen retention threshold of 64Cu-ATSM in hypoxic plaque.
It be either higher or lower than pimonidazole (pO2 ≤ 10mm Hg), resulting in smaller or larger
spatial distribution of 64Cu-ATSM than PIMO.
Although 18F-FDG has been a well-described agent for in vivo imaging of atherosclerosis in animal
(115, 125) and human subjects (15) and there is strong experimental and clinical evidence
supporting that the increased

18

F-FDG uptake in atherosclerotic plaque is associated with the

abundance of macrophages, it is a relatively non-specific tracer with many practical limitations
(126) because it provides complementary information on metabolic function as opposed to
hypoxia. 18F-FDG vascular uptake can also present in vascular smooth muscle cells and endothelial
cells (72, 127). Moreover, because of the long time course of

18

F-FDG in arteries, a longer 18F-

FDG circulation time is always required for vascular 18F-FDG PET imaging protocol, preferably
at least 90 minutes (128). One other hand, the rapid blood pool clearance of 64Cu-ATSM allowed
PET imaging within 30 min of tracer injection, a significant advance over 18F-FDG. Our finding
that the SUV and A/M SUV ratios between HFD and SCD ApoE-/- with
differ from a previous study using

18

64

Cu-ATSM imaging

F-FDG as the PET imaging agent where ApoE-/- mice

receiving SCD had stable and low 18F-FDG SUVs while the ApoE-/- mice receiving HFD showed
progressively higher 18F-FDG uptake up to the end of their study at 32 weeks (115). This difference
may be secondary to the different retention mechanisms between
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64

Cu-ATSM and

18

F-FDG. It

implies that the either the oxygen tension (<1% oxygen (129)) is not low enough to be
distinguished by

64

Cu-ATSM imaging or alternatively, this finding may also suggest that the

relative effect of the ApoE-/- mouse model genetics is stronger than the effect of diet on hypoxia
progression in atherosclerotic plaque, or a combination of these reasons.
Further studies could be performed using logistic regression analysis to compare immunoreactivity
scores of PIMO-determined hypoxia in the plaques as well as other immunohistochemistry
markers of hypoxia (HIF 1α, HIF 2α and VEGF) to the continuous variable of SUV, and to the
A/M SUV ratios post injection of 64Cu-ATSM. HIF-1α and HIF-2α are often used as markers of
hypoxia. The expression of VEGF is low in normal vessel wall and up-regulated by hypoxia,
inflammatory mediators, and certain growth factors. The human study from Slumer et al. in 2008
(26) demonstrated increasing expression of these hypoxia markers over the development of
atherosclerosis. Nevertheless, another study using an atherosclerotic murine model found that all
three markers of hypoxia correlated negatively with SUVmean of 18F-FDG (115). The discordant
finding was explained by the limited number of lesions investigated in the human study, smaller
lesions in mice compared to human, and potentially dissimilar gene expression of molecular markers of
hypoxia between and mice and human, etc. In future studies, we can validate whether these hypoxia markers
will correlate positively with the uptake of 64Cu-ATSM to provide more data to explain this discrepancy.

One limitation in the study is the relatively poor spatial resolution of the small animal PET and
coregistered CT scanner. The diameter of mouse aortic arch is about 1 mm (130), which is at the
same level of the small animal PET resolution (1-2 mm). As a result the effect of partial volume
and spillover may deteriorate the imaging quality and cause underestimation the resultant
radioactivity. In further studies we will increase the size of animal model from mouse to rabbit,
and apply post-processing techniques to correct for partial volume effects. The tiny size of the
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mouse aortic arch, which may easily generate shift and deformation during obtaining adjacent
sections for autoradiography and immunohistochemistry, together with the dramatic different
resolution of the autoradiography plate scanner (50 um) and the confocal microscope (< 5 um),
brings up technical difficulty to correlate the autoradiograph and immunohistochemistry images
at the pixel level.
In order to justify the activity in the thigh muscle as the background activity for uptake
normalization purposes, we collected the samples of aortic arch (with heart attached), blood pool
and leg muscle from at least three SCD ApoE-/- mice and control mice after sacrificing (30 minute
post injection of 64Cu-ATSM). For the ApoE-/- mice, the %ID/gram of aortic arch with heart (4.02
± 0.69) was 1.5 time higher than that of blood (2.72 ± 0.18), and 5.1 times higher than that of
muscle (0.79 ± 0.11). However, for the control mice the %ID/gram of aortic arch with heart (2.34
± 0.56) showed a similar value with blood (2.30 ± 0.60), and was 3.9 times higher than the muscle
(0.61 ± 0.12). These findings suggest that activity of tracer in muscle is the same between the
groups.
In summary, we evaluated the presence of hypoxia in a mouse model of atherosclerosis using 64CuATSM. This PET imaging agent is demonstrated to be superior to

18

FDG in terms of imaging

hypoxia in atherosclerotic plaques and high image contrast between hypoxic and normoxic tissues
7.5-30 minutes post injection. The results of longitudinal study suggested that genetic factor was
a more important reason than environment (e.g. diet) in the development of atherosclerosis.

3.2 64Cu-ATSM PET/MR imaging of hypoxic atherosclerotic
plaque in a rabbit model
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This section was previously published as “PET/MRI of hypoxic atherosclerosis using 64CuATSM in a rabbit model” in Journal of Nuclear Medicine (131). Copyright (2016) by the Society
of Nuclear Medicine and Molecular Imaging, Inc.

3.2.1

64

Cu-ATSM rabbit study: introduction

Hybrid PET/MR imaging modalities provide complementary information to aid in the diagnosis
and stating of cardiovascular disease. MR imaging provides superior soft-tissue contrast even in
the absence of intravenous MR contrast agents, and multiple MR sequences can be acquired to
better clarify tissue and lesion characteristics in a single imaging session. Simultaneous acquisition
of MR imaging sequences and PET data avoid image mis-registration and is ideal when using both
PET and MR imaging to study rapidly changing biologic processes. In addition, since MR imaging
does not use ionizing radiation, PET/MR offers the additional benefit of lower radiation dosimetry
than the PET/CT.
Due to the above benefits, we investigated 64Cu-ATSM in a PET/MR hybrid scanner for detecting
hypoxic atherosclerosis in a rabbit model. The PET/MR imaging strategy uses MRI for attenuation
correction and for co-localization of 64Cu-ATSM uptake on PET to the rabbit femoral artery lesion
depicted anatomically on a 3 Tesla MR image. We showed that 64Cu-ATSM could detect hypoxia
in this animal model with atherosclerotic-like lesions and that hypoxia in these lesions as
determined by 64Cu-ATSM uptake on PET and PIMO staining of the ex-vivo specimen obtained
after imaging co-localized to macrophages.
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3.2.2

64

Cu-ATSM rabbit study: materials and methods

I. General
Animal studies were performed under a protocol approved by the Animal Studies Committee at
our institution. Advanced atherosclerotic-like lesions were induced in the right femoral arteries of
5 New Zealand White rabbits weighing 2.5-3 kg by endothelial denudation with air desiccation 24 wk after the start of a Western diet (0.25% cholesterol, Purina TestDiet, Indianapolis, TN) (132,
133), depending on when the serum cholesterol level of the rabbits exceeded 2 mg/mL. The left
femoral artery underwent a sham operation as the negative control. At the end of the last imaging
procedure, the anesthetized animals were euthanized by exsanguination and the arterial segments
collected for IHC.
64

Cu was prepared as previously described (see section 2.4.2.1).
II. Imaging protocol
The rabbits underwent simultaneous PET/MR (Siemens Biograph mMR) examination 4 and 8

wk after arterial injury operation (Fig. 17). At each time-point, a 0-60 min dynamic whole-body
PET/MR exam was performed post-injection (p.i.) of ~111 MBq 64Cu-ATSM. At the second time
point, an additional 0-75 min dynamic PET/MR exam p.i. of ~111 MBq 18F-FDG was performed
one day prior to the 64Cu-ATSM imaging.
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Figure 17 Study protocol for imaging atherosclerosis rabbits.

During PET acquisition, MR scans consisted of T1-weighted 2D turbo-spin-echo (TSE) (TR/TE =
600/11 ms, number of slices = 16, field of view = 60×120 mm, interpolated matrix size = 384×768,
signal averages = 12 ), T2-weighted 2D TSE (TR/TE = 2200-2890/56 ms, number of slices = 16,
field of view = 60×120 mm, matrix size = interpolated 384×768, signal averages = 10), and proton
density (PD)-weighted 2D TSE (TR/TE = 2200-2890/11 ms, number of slices = 16, field of view
= 60×120 mm, interpolated matrix size = 384×768, signal averages = 10) were obtained. For all
sequences, magnetic field strength = 3T, pixel bandwidth = 260 kHz, echo train length = 7, inplane resolution = 0.16×0.16 mm, and slice thickness = 2 mm.
MR-based 2-point Dixon attenuation correction for the PET image was performed. The data from
the last 30 min of each PET scan was used for high-definition (HD) PET imaging reconstruction,
performed on the Siemens e7-tools software using point spread function corrected ordinary
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Poisson ordered subsets expectation maximization (PSF-OP–OSEM) algorithm with 21 subsets, 8
iterations, and a 2-mm full width at half maximum (FWHM) Gaussian smoothing filter. The size
of the image matrices were 344×344×127 resulting in a pixel size of 1.04 mm and a slice thickness
of 2.03 mm. Dynamic images were decay corrected to the injection time. An average PET spatial
resolution of 4.3 mm at 1 cm offset from the center of field of view was expected to be obtained
from the PET/MR scanner (134).
III.

Image analysis

PET images were co-registered with MR images using Inveon Research Workplace (IRW;
Siemens Medical Solutions USA, Inc., Malvern, PA) to identify the location of the plaques
developed in the femoral artery. The fused images were evaluated by measuring the radioactivity
concentration within the regions of interests drawn on the injured femoral artery (IF), shamoperated femoral artery (SF) and a representative area on the non-target background thigh muscle
(BM) of each rabbit.
The mean and maximum of standardized uptake values (SUVmean and SUVmax) of IF, SF, and BM
were calculated by dividing the decay-corrected activity per unit volume of tissue (Bq/cm3) by the
injected activity per unit of body weight (Bq/g), as described previously.
The mean cross-sectional area of the femoral artery blood vessel wall was measured in transverse
T1-weighted images that show the best contrast between lumen and vessel wall by subtracting the
number of pixels of the inner blood vessel area from the outer blood vessel area in transverse MR
images and taking the average of the slices containing the plaque.
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IV.

Histologic analysis

The animals were injected intravenously with the hypoxia-reactive reagent PIMO hydrochloride
(Hypoxyprobe-1, Natural Pharmacia International, Belmont, MA) 1.5-2 h before euthanasia. A
vitamin capsule as an external marker was used to match injured vessel site and the MRI image
volume.

The IF and SF were collected and perfusion-fixed with freshly prepared 3-4%

paraformaldehyde (PFA) solution to collect specimens for histopathological assessment.
Specimens were embedded in paraffin and sectioned transversely. To visualize the spatial colocalization of the hypoxic cells and macrophages, adjacent 5 µm thick cross-sections of the
femoral artery were obtained.
IF and SF specimens were stained for the presence of hypoxia using the anti-pimonidazole
antibody (Natural Pharmacia Inc., Belmont, MA) and mounted in solution containing 4'-6diamidino-2-phenylindole (DAPI; Vector Laboratories, Palo Alto, CA) for fluorescent staining of
nuclei. Although PIMO may react with reactive oxygen species, the anti-pimonidazole antibody
only recognizes hypoxia derivatives (26). Fluorescein isothiocyanate was used as the secondary
antibody.
Adjacent serial sections were assessed for macrophage content and hypoxia inducible factor-1α
(HIF-1α) using mouse monoclonal antibodies for rabbit macrophages (clone RAM-11, Dako North
America, Inc., Carpinteria, CA) and anti-HIF-1α (clone H1α67, Novus Biologicals, Littleton, CO).
The bound markers were detected by Cy3 and Cy2 secondary fluorescent antibodies, respectively.
The slides were incubated with DAPI prior to cover-slipping. Negative control staining was
performed by replacing the primary antibody with a matching isotype control followed by the same
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fluorescent-labeled secondary antibody. IHC slides were imaged with use of a Leica TCS SP5
confocal laser scanning microscope.
V.

Statistical methods

Data are presented as mean ± standard deviation (SD). Statistical analysis was performed using
GraphPad Prism 6 (GraphPad Sofrware, Inc., La Jolla, CA). Differences between the IF/BM and
SF/BM SUV were assessed using the Student’s t-test. The correlation between the IF/SF crosssection area ratios in MR images and the IF/SF SUV ratios in the corresponding 64Cu-ATSM PET
images were analyzed by simple linear regression with 95% confidence intervals. P < 0.05 was
considered statistically significant.

3.2.3

64

Cu-ATSM rabbit study: results

PET/MR imaging showed increased uptake of

64

Cu-ATSM in the IF of all 5 rabbits 4 wk after

injury, as indicated by the bright spots in both transverse and coronal views co-localizing to the
lesion as identified by anatomic MRI (Fig. 18, A and D; Fig. 19). Eight weeks post injury,
significantly higher 64Cu-ATSM was found in IF in the PET images fused with T1-weighted MRI,
T2-weighted MRI and PD-weighted MRI (Fig. 18, B and E; Fig. 20, PD-weighted MRI not shown).
Higher uptake of

18

F-FDG in the IF of the rabbits confirmed the development of advanced

atherosclerotic-like plaque (Fig. 19, C and F; Fig. 21).
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Figure 18 The transverse (top) and coronal (bottom) view of 64Cu-ATSM PET/T1-weighted MR images of a
representative rabbit 4 wk (A, D) and 8 wk (B, E) post injury, and 18F-FDG PET/ T1-weighted MR images of the same
rabbit 8 wk post injury (C, F). Red arrows point to injured femoral artery; blue arrows point to sham-operated femoral
artery.
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Figure 19 64Cu-ATSM PET/MR images of a representative rabbit shown in Figure 21 4 wk post injury. The transverse
(top) and coronal (bottom) view of the PET images (A, D), T1-weighted MR images (B, E) and fused PET/MR images
(C, F) indicated a significantly elevated uptake of 64Cu-ATSM in the IF as compared to the SF. Red arrows point to
injured femoral artery; blue arrows point to sham-operated femoral artery.

Figure 20 64Cu-ATSM PET/MR images of the same representative rabbit shown in Figure 21 8 wk post injury.
Significant uptake of 64Cu-ATSM was also found in the IF as compared to the SF as shown in transverse (top) and
coronal (bottom) views of the PET images alone (A, F), fused either with T 1-weighted MR images (MR: B, G; fused
PET/MR: C, H) or T2-weighted MR images (MR: D, I; fused PET/MR: E, J). Red arrows point to injured femoral
artery; blue arrows point to sham-operated femoral artery.
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Figure 21 18F-FDG PET/MR images of the same representative rabbit shown in Figure 21 8 weeks post injury. The
transverse (top) and coronal (bottom) view of the pure PET images (left, A, D), pure MR images (middle, B, E) and
fused PET/MR images (right, C, F) showed a higher uptake of 18F-FDG in the IF as compared to the SF. Red arrow
points to injured femoral artery; blue arrow points to sham-operated femoral artery.

The IF demonstrated 1.75 ± 0.21, and 2.30 ± 0.26 fold higher SUVmean ratios and 1.61 ± 0.15, and
1.84 ± 0.12-fold higher SUVmax ratios 30-60 min p.i. of 64Cu-ATSM in comparison to the SF 4
and 8 wk after injury (Fig. 22), respectively.

18

F-FDG imaging demonstrated 2.31 ± 0.29 IF/SF

SUVmean ratios and 1.82 ± 0.26 IF/SF SUVmax ratios 4 and 8 wk after injury (Fig. 22). IF/BM SUV
ratios were significantly higher (P < 0.001) than SF/BM SUV ratios both 4 and 8 wk after injury
p.i. of 64Cu-ATSM and 8 wk after injury p.i. of 18F-FDG (P < 0.05) (Fig. 23).
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Figure 22 IF/SF SUVmean (A) and SUVmax (B) of the rabbits in both 64Cu-ATSM and 18F-FDG images increased over
time after injury.

Figure 23 IF/BM SUVmean ratios were significantly higher than SF/BM SUV mean ratios 4 and 8 wk post injury in 64CuATSM imaging, and 8 wk post injury in 18F-FDG imaging.

IF/SF SUV ratios measured from 64Cu-ATSM PET images did not show a significant correlation
with specific signal on T1, T2, or PD-weighted MR images. Nevertheless, the combination of all
three sequences helped to delineate the plaque and lumen boundaries. The ratios of IF/SF blood
vessel wall cross-sectional areas determined by T1-weighted images was strongly positively
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correlated to IF/SF SUVmean ratios in a linear regression (R2 = 0.742, P = 0.0002) (Fig. 24). This
finding suggested an increasing lipid content and hypoxic level in the IF during the progression of
atherosclerosis, as supported by the thickening of the IF blood vessel wall.

Figure 24 (A) Fused PET/MR image suggests a thickened arterial wall and elevated uptake 64Cu-ASTM in the IF as
compared to the SF. (B) Linear regression analysis shows that 64Cu-ATSM PET IF/SF SUVmean ratios are positively
correlated to IF/SF cross-section area ratios measured in T 1-weighted MRI images.

Hematoxylin and eosin (H&E) stain demonstrated a focal thickened neointima comprised of foam
cells and vascular smooth muscle cells was generated in the injured vessel (Fig.
25). Immunohistochemical analysis showed that the induced atherosclerotic-like lesions contained
macrophages as indicated by RAM-11, which co-localized to the HIF-1α positive area (Fig. 26, A,
B and D). Hypoxia, as shown by PIMO staining of the adjacent section, was located in the deep
macrophage-rich area within the atheromatous core of the plaque (Fig. 26, C; Fig. 27). Superficial
macrophages adjacent to the lumen stained negatively with PIMO, suggesting that these superficial
macrophages were not hypoxic (Fig. 27), consistent with what has been described previously
(119). No immunofluorescence of RAM-11, HIF-1α, or PIMO was seen in the sham-operated
femoral artery sections (Fig. 28).
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Figure 25 Hematoxylin and eosin (H&E) stain of the sham-operated (control) femoral artery (left) and injured femoral
artery (right) in 4X (top) and 10X (bottom) magnification shows that feeding cholesterol-enriched diet and air
dessication produced a focal thickened neointima in the area of previous air dessication that was comprised of foam
cells, and vascular smooth muscle cells. The duration of cholesterol diet was too short to see lesions induced in
peripheral arteries other than the one associated with air dessication.

56

Figure 26 In the atherosclerotic plaque of the injured femoral artery, HIF-1 staining is localized within areas of high
RAM-11-positive macrophages (A), confirmed by viewing single channels staining of RAM-11 (B) and HIF-1 (D).
Detection of pimonidazole (PIMO) adducts was done on the adjacent slide (C), and pimonidazole positivity was
observed in the area of RAM-11+HIF-1 displayed in panels A, B and D. Panels A and C are at the same scale. For
all panels the color code is as follows: DAPI, white; RAM-11, red; HIF-1, blue; PIMO, green.
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Figure 27 Area scan containing the injured femoral artery depicted in Figure 29 shows the presence of both deep and
superficial macrophages in RAM-11 staining which are co-localized to HIF-1 staining. However, only deep
macrophage-rich area is pimonidazole positive, as displayed in Figure 4(C). The color code is as follows: DAPI, white;
RAM-11, red; HIF-1, blue.
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Figure 28 Immunofluorescence images of the sham-operated femoral artery showing that neither Ram-11 nor HIF1α were positively stained in this region. Red observed is red blood cells (non-nucleated). Images of PIMO staining
from the adjacent section (no positive results) were not included in this figure.

3.2.4

64

Cu-ATSM rabbit study: discussion

In this study, we demonstrated the ability of 64Cu-ATSM PET to noninvasively detect hypoxia in
advanced atherosclerosis-like lesions in rabbit model. To our knowledge, this study is the first
investigation of 64Cu-ATSM as a hypoxic cell PET imaging agent in a non-murine animal model
of atherosclerosis, and it suggests that 64Cu-ATSM PET/MR is a promising imaging method for
detecting hypoxic and potentially vulnerable atherosclerosis in human subjects.
Although PET/CT as a hybrid scanner has in the past emerged as a valuable modality in clinical
use as well as an important research tool, the fully integrated PET/MR scanners provide the
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excellent soft tissue contrast and functional imaging capabilities of MR (135). The described
morphological features of plaque vulnerability can be nicely imaged by MRI (136) and the
biological features of plaque vulnerability can be visualized by PET with different tracers and
targets in a complementary fashion (137-139). Thus PET/MR allows for multiparametric profiling
of plaque morphology and potentially vulnerability in one imaging session and should facilitate
the identification of high-risk plaques in patients with atherosclerotic disease (135). These nononcological applications may further benefit from lower radiation exposure of the patients in
PET/MR compared to PET/CT (140). In light of these advantages, imaging of atherosclerosis
using fully integrated hybrid PET/MR yields an additional diagnostic value both over stand-alone
PET and MR scanners and as well as over hybrid PET/CT.
The H&E stain, along with our previous work (133), showed that a combination of a cholesterolenriched diet and air dessication produced a focal thickened neointima in the area of air dessication
comprised of foam cells and vascular smooth muscle cells. The duration of cholesterol diet in
these animals was too short to see lesions induced in peripheral arteries outside of the region of air
dessication, thus allowing us to use the contralateral sham artery as a control. The hypoxia-specific
dye PIMO used for histopathologic characterization ex vivo is a 2-nitroimidazole containing a
basic, piperidine moiety and reduces in cells with low oxygen tension. It is considered as the “gold
standard” immunohistochemical hypoxia marker and widely used as a hypoxia-specific dye (pO2
≤ 10 mm Hg). The resulting PIMO derivatives form protein adducts, which can be detected by
immunostaining (24). This agent has been used primarily in oncologic specimen assessment (25)
and only recently in assessment of atherosclerosis (26). The co-localization of the macrophage
marker (RAM-11) and hypoxia indicators (PIMO) suggested the uptake of

64

Cu-ATSM was

associated with the presence of macrophages. Despite stimuli other than hypoxia that may induced
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HIF-1 in normoxia (141), a previous study (119) demonstrated that nearly all macrophages present
in the plaque expressed HIF-1α, and a strong correlation between the hypoxic region (PIMO) and
macrophage (RAM-11) density in plaque by immunohistology. Thus, the presence of HIF-1α in
the same region as the macrophages in the lesions served as supportive evidence of hypoxia in
atherosclerotic macrophages. In addition, the finding that hypoxia was mainly located in the deep,
macrophage-rich area within the atheromatous core was consistent with this study (119), which
suggested that enough oxygen could diffuse from the lumen to nourish the shallow macrophage
population but not the deep macrophage-rich core owing to the increased consumption and/or
reduced supply of O2 and nutrients from the lumen and vasa vasorum to those regions. The
significantly higher

18

F-FDG uptake in the injured femoral artery further helped to confirm the

development of advanced plaque and accumulated macrophages in this region. In previous
publications, it was shown that macrophages have a high uptake of

18

F-FDG (125). Moreover,

even though we did not assess the biodistribution of 64Cu-ATSM in blood, muscle, and femoral
arteries to validate the complete clearance of radiopharmaceuticals at the time periods used for
SUV calculation, our methods for SUV comparison – injured femoral to sham femoral SUV ratios
– show the absence of radioactivity in the blood pool excluding potential bias that could result
from the radioactivity contribution from the blood pool (125).
Similar to the 64Cu-ATSM PET imaging study of mice, an important limitation of our study is that
the SUVs were not corrected for partial volume effects (PVEs). The quantitative accuracy of PET
is reduced by PVEs primarily due to the limited spatial resolution of the scanner leading to
underestimation of the SUV with decreasing structural size of plaques (142, 143). In practice, PVE
is minimal when the dimensions of homogenous uptake region are > 2- to 3-times the spatial
resolution of the scanner (144). The spatial resolution of the Siemens mMR PET/MR system is
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approximately 4.3 mm (134, 145), while the rabbit’s femoral artery is 1.5-1.8 mm in diameter
(146). As a result, quantification of tracer uptake in rabbit atherosclerotic plaque is likely to be
significantly affected by PVEs. Therefore, it is necessary to apply PVEs correction techniques to
exploit the ability of PET/MR to provide high resolution PET images for improved absolute
quantitative assessment of hypoxia in atherosclerotic plaque.
Furthermore, in this project, we used standard multi-contrast MRI sequences to image femoral
arterial plaque with the initial intent of identifying plaque components in this rabbit model of
atherosclerosis. However, because of the relatively small plaque size, limited MRI spatial
resolution, and simple plaque components (smooth muscle cells and foam cells), it was difficult to
consistently differentiate plaque components by this approach and to obtain quantitative plaque
composition information from MR images to conduct specific studies correlating MRI
characteristics of atherosclerosis with PET signal.

3.3 64Cu-ATSM PET/MR imaging of hypoxic atherosclerosis
in human carotid artery
We made significant strides in demonstrating that the hypoxic cell PET imaging agent 64Cu-ATSM
could be used for the imaging of hypoxic plaque with animal studies, and collected preliminary
data to support further studies to fully validate the feasibility of imaging the extent of hypoxia in
patients with carotid atherosclerosis.
PET/MRI of human atherosclerosis in the carotid arteries has so far been focused primarily on
FDG (147). Several studies have used sequential PET and MRI for imaging atherosclerotic plaques
in human carotid arteries (148-152). However, we were the first group who used 64Cu-ATSM as
the PET contrast agent to target hypoxia in human carotid atherosclerosis.
62

Our IND (125353) for a pilot clinical trial to determine whether 64Cu-ATSM PET/MR scanning is
capable of detecting hypoxic carotid atherosclerosis in human subjects was approved by the FDA
for initiation of the human study.

3.3.1

64

Cu-ATSM patient study: materials and methods

9 patients with carotid atherosclerosis with percent stenosis of at least ≥ 50% diameter as diagnosed
by Doppler ultrasound were recruited from the vascular surgery clinic of Dr. Mohamed Zayed and
his colleagues.

64

Cu-ATSM PET imaging with simultaneously-acquired dedicated MR imaging

for carotid plaque anatomic characterization was performed in 7 patients (two were claustrophobic
and couldn’t tolerate the imaging). Of these 7 patients, in 6 patients imaging was of diagnostic
quality. Imaging was non-diagnostic in one secondary to patient motion.
I.

PET-MRI imaging protocol

64

Cu-ATSM was prepared as described previously using commercially available GMP

radiopharmaceutical kits. All patients underwent simultaneous PET and MRI examination of the
carotid arteries on a PET/MRI systems (mMR, Siemens Medical Solution, Erlangen, Germany)
equipped with a state-of-the-art bilateral 4 channel phased-array small field carotid coils (153).
The coils allowed for sub-millimeter resolution of the carotid lumen, vessel walls and
atherosclerotic plaques. The purpose of the MRI scan was to determine various plaque components
(lipid core, calcification, intraplaque hemorrhage) with submillimeter spatial resolution that was
far better than that of PET imaging which had an in-plane resolution of 4 mm at best. This allowed
direct correlation of plaque components to the 64Cu-ATSM signal identified on PET imaging. After
the scout imaging to localize the carotid arteries in 3 orthogonal planes, a scan for attenuation
correction (AC) was performed. Then a 3D T2-weighted SPACE sequence was executed to obtain
an isotropic 3D data set of dark-blood carotid artery images. This data set was used to determine
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the orientation of both right and left carotid arteries in coronal orientation. The imaging parameters
was: TR/TE=1500 ms/236 ms, bandwidth = 574 Hz/pixel, flip angle = 120o, FOV = 180×134 mm2,
matrix size = 256×192, total 56 slices, average number = 2, slice thickness = 0.7 mm, coronal
plane, and scan time = 7 min.
After localizing the carotid arteries, 18-20 mCi of

64

Cu-ATSM was injected intravenously. The

following MR scans were performed simultaneously with the PET acquisition. To insure that the
64

Cu-ATSM uptake was optimally imaged, PET imaging was acquired in list mode over the entire

60-min MR acquisition period. If additional time was needed to achieve optimum radiotracer
distribution, patients would be rescanned at 90 minutes post injection. All MRI techniques were
well established and had been used extensively by our group (154). These included:
1. Dark Blood T1-weighted: The MRI sequence was TSE sequence with echo sharing and no
ECG triggering. Superior and inferior pre-saturation bands was used to suppress blood
signal. Imaging parameters were: TR/TE=700-800 ms/8 ms, FOV=140× 140 mm2, matrix
size = 256×256 and was interpolated to 512×512, pixel size = 0.27×0.27 mm2, bandwidth
= 345 Hz/pixel, echo train length = 13, signal average = 2, 18 slices, no slice gap, and slice
thickness = 3 mm. These image resolution and volume coverage were exactly the same as
following scans.
2. Dark Blood T2, Proton Density-weighted: TR/TE1/TE2= 2000 ms/8 ms/45 ms, signal
average = 2.
3. Bright blood 3D gradient-echo (GRE) T1-weighted time of flight (TOF): TR/TE = 25/3.5
msec, flip angle = 25o, signal average = 2.
II.

PET/MR data analysis

64

PET data demonstrating plaque wall radiotracer activity would then be summed over the
appropriate time frames during reconstruction. The 30-60 min data from each PET scan was used
for high-definition (HD) PET imaging reconstruction, performed on the Siemens e7-tools software
using point spread function corrected ordinary Poisson ordered subsets expectation maximization
(PSF-OP–OSEM, or simply PSF-OSEM) algorithm with 21 subsets, 8 iterations, and a 2-mm full
width at half maximum (FWHM) Gaussian smoothing filter. The size of the image matrices were
344×344×127 resulting in a pixel size of 1.04 mm and a slice thickness of 2.03 mm. MR-based 2point Dixon attenuation correction for the PET image was also performed. Dynamic images were
decay corrected to the injection time. MR image was fused with reconstructed PET image on
Inveon Research Workplace (IRW; Siemens Medical Solutions USA, Inc., Malvern, PA). All 2D
MRI images were used for determining location and extension of the plaque components. Carotid
PET images were assessed for visual uptake of 64Cu-ATSM and SUV and plaque-to-background
SUV ratios.
III.

Ktrans measurement

a. DCE-MR imaging protocol
For two of the patients who agreed to undertake dynamic contrast enhancement magnetic
resonance imaging (DCE-MRI), simultaneous to the

64

Cu-ATSM PET scanning, DCE-MR

imaging was performed between acquisition of pre- and post-contrast TSE imaging sections.
Three-dimensional DCE T1-weighted fast field-echo images were acquired by obtaining 14
transverse over-contiguous sections for 20 time frames with a separation of 12.5 seconds between
frames. Total imaging time was approximately 4 minutes (250 seconds). Contrast material was
intravenously injected at the beginning of the third time frame with use of a power injector.
Contrast material was injected at a rate of 0.5 mL/sec, followed by injection of a 20-mL saline
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flush at the same rate. Relevant imaging parameters were as follows: spatial resolution,
0.703×0.703 mm2; section thickness, 3.0 mm; field of view, 18×18 cm; and matrix size, 256×256.
A spatial saturation slab at the caudal position parallel to the imaging plane was added to reduce
inflow artifacts.
b. Pharmacokinetic Modeling
The contrast agent dynamics was quantified using the standard Patlak kinetic model for the DCEMR images. This pharmacokinetic model is based on the two-compartment model (Fig. 29) and
model assumes that a well-mixed tracer exists in each of the compartment in a uniform
concentration. A third (intracellular) compartment is assumed to exhibit no uptake of contrast
agent.

Figure 29 Schematic illustration of pharmacokinetic parameters used in two-compartment models to describe the
microvasculature in atherosclerotic plaque microvasculature. vp represents the fractional blood volume; ve represents
the fraction of the extracellular extravascular space (EES); Ktrans is the contrast medium transfer rate from the
microvasculature to the EES, while Ktrans/ve describes the reflux. (Adapted and modified from "Dynamic ContrastEnhanced MRI to Study Atherosclerotic Plaque Microvasculature," by Raf H. M. van Hoof, Sylvia Heeneman,
Joachim E. Wildberger, and M. Eline Kooicorresponding, 2016, Curr Atheroscler Rep, Volume 18, p33. Copyright
(2016) by title of publisher and is distributed under the terms of the Creative Commons Attribution 4.0 International
License.)
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The DCE-MR images were analyzed to generate signal enhancement curves of discrete data points
for each of the pixels in the images (raw data, Ct), including the carotid plaques and blood vessel
walls. Cp was determined by curve fitting the arterial or vascular input function (AIF/VIF) with
data points from a 3-mm-diameter circular ROI in the center of the jugular vein at the most caudal
section, using a slightly adapted equation introduced by Parker et al (155), as follows:
𝐴

𝐶𝑝 (𝑡) = 𝜎√2𝜋 𝑒

−

(𝑡−𝑇)2
2𝜎2

𝛼𝑒 −𝛽𝑡

+ 1+𝑒 −𝑠(𝑡−𝜏) ,

(2)

where A, σ, and T are the scaling constant, width, and center of the Gaussian, respectively; α and
β the amplitude and decay constant of the exponential function, respectively; and s and τ the width
and center of the sigmoid, respectively.
Measurements of Ct and Cp over time—assumed to be linearly proportional to the change in signal
intensity of the contrast agent in the tissue and blood (156) —are sufficient to solve for Ktrans and
vp by for each voxel separately by curve fitting the equation 𝐶𝑡 (𝑡) = 𝑣𝑝 𝐶𝑝 (𝑡) +
𝑡

𝐾 𝑡𝑟𝑎𝑛𝑠 ∫0 𝐶𝑝 (𝜏) 𝑑𝜏. The maps of Ktrans and vp values on a pixel-by-pixel basis were created
accordingly.
The curve fitting process was performed by the least-squares curve-fitting routine lsqcurvefit.m
MATLAB (MathWorks) function with Gauss-Newton optimization. To exclude nonphysical
solutions, the values of Ktrans were constrained to the maximum of 1 and minimum of 0. This
enabled generation of the maps of Ktrans and vp values on a pixel-by-pixel basis with which to assess
plaque heterogeneity. The relative fit errors (RFE) errors that indicated the ability of the model to
describe the data was calculated as follows:
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∑(𝐶𝑡,𝑓𝑖𝑡 −𝐶𝑡 )2

𝑅𝐸𝐹 = √

∑ 𝐶𝑡2

,

(3)

where Ct,fit is the fitted tissue concentration and Ct is the measured tissue concentration at the
sampled time points. The mean and standard deviation REF was calculated over all voxels.
III.

Immunohistochemistry analysis

One of the 6 patients with diagnostic PET/MRI images underwent endarterectomy surgery. This
patient was administered PIMO (0.5 g/m2) orally 2 h prior to the scheduled standard of care
endarterectomy. At the time of surgery, a research coordinator/assistant was sent to the operating
room to collect each endarterectomy specimen in normal saline. Specimens were refrigerated
immediately at 4ºC and was processed within 4 hrs. Because PIMO has been shown to detect
hypoxia in normal skin, we also asked the surgeon to provide us a small specimen of normal skin
taken at the site of surgery as a positive PIMO control.
The carotid endarterectomy specimen as well as autopsy specimens from ~5 normal subjects as
controls were processed, decalcified (when necessary), embedded in paraffin and sectioned
transversely. Serial 5-m sections from every 4 mm intervals was placed on slides for IHC and
The endarterectomy specimen and skin specimen (but not autopsy controls who had received no
prior oral administration of PIMO) were stained for the presence of hypoxia using the antiPIMO
antibody (Natural Pharmacia Inc., Belmont, MA). Sections were also stained with primary
antibodies against HIF-1α (clone H1α67, Novus Biologicals, Littleton, CO) and macrophages
(CD68) and hypoxia was co-localized to the presence of HIF-1α and CD68. IHC slides were
imaged with use of a Leica TCS SP5 confocal laser scanning microscope. Standard hematoxylin
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and eosin (H&E) and/or Verhoeff Van Gieson (VVG) staining was also performed in both the
endarterectomy specimen and in the autopsy controls.

3.3.2

64

Cu-ATSM patient study: results

For 6 of the 7 patients with acceptable image quality, all were asymptomatic but showed plaques
in either carotid artery or vertebral artery. Two patients had uptake of

64

Cu-ATSM in carotid

plaques (Fig. 30), while 3 had uptake in vertebral plaques (Fig. 31, Table 2). The 30-60 minute
target-to-background (T/B) 64Cu-ATSM SUV ratio was 2.03 ± 0.18.
Table 2 Summary of 64Cu-ATSM PET/MR detection of plaques in the carotid artery and vertebral artery of
the patients. “+” stands for positive detection in the corresponding image modality, while “-” stands for a
negative imaging result.
Patient
#

Carotid artery
Left

Vertebral artery
Right

Left

Right

MR

PET

MR

PET

MR

PET

MR

PET

1

-

-

+

-

+

+

-

-

4

+

-

+

-

+

+

-

-

5

-

-

+ (little)

-

+

+

+

+

6

-

-

-

-

+

-

(blurred)

-

7

+

+

-

-

+

-

-

-

8

+

+

-

-

+

-

-

-
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Figure 30 64Cu-ATSM uptake in lipid-rich necrotic core (LRNC) of the plaque in the left carotid artery as shown in
the transverse view of (A) 64Cu-ATSM PET/T1-weighted MR image and (D) zoomed-in PET/MR image with the
region of interest in the carotid artery of a representative patient. Plaque components of LRNC and recent hemorrhage
were visible in the corresponding (B) T 1-weighted MRI, (C) T2-weighted MRI, (D) PD-weighted MRI, (F) Time of
flight MRI.

Figure 31 64Cu-ATSM uptake in plaques of vertebral artery as shown in the transverse view of (A)
PET/T1-weighted MR images and (B) T 1-weighted MR images of a representative patient.
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Cu-ATSM

DCE MR imaging exhibited an initial and abrupt increase in signal intensity (contrast agent
concentration) in the jugular vein after contrast material administration, while the signal intensity
in the internal carotid artery was roughly a continued slower rise (Fig 32). Contrast agent
concentration–time curve for each pixel in the region of interests that included the carotid plaques
and surrounding tissues were plotted by curve fitting the Patlak model (Fig. 33). The RFE to fit
this pharmacokinetic model was 28.6% ± 7.9% which was comparable to the values reported in
literature (4). Qualitative evaluation of Ktrans map showed that the highest Ktrans values were at the
rims of carotid plaque (Fig. 34). This finding was consistent with literature that the necrotic core
exhibited low Ktrans values at center of plaque, while the highly vascularized adventitia at the outer
rim and the region near inner rim of the plaque have high Ktrans values (4).

Figure 32 Representative DCE-MR images of one patient with 64Cu-ATSM uptake in internal carotid artery plaque.
(A) PET/T1-weighted MR image, (B) T1-weighted MR image.DCE-MR images (157) (targeting the region in images
A and B identified by the blue box) (C) before contrast material administration, (D) 0.6 minutes after injection (bolus
arrival), and (E) 2.5 minutes after injection, respectively
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Figure 33 Plaque concentration–time curve fit to the Patlak model. AIF (Cp) concentration-time curves were fit using
a slightly adapted formula introduced by Parker et al (155). Mean parameters used to construct the general VIF were
as follows: scaling constant of Gaussian = 140 SI⋅ min, center of Gaussian = 0.65 minutes, width of Gaussian = 0.15
minutes, amplitude = 255.3 SI, decay constant = 0.052 min -1, width of sigmoid = 15 min-1, and center of sigmoid =
0.8 minutes. SI = MR signal intensity which was assumed to be proportional to contrast agent (Gd-DTPA)
concentration in mmol.
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Figure 34 Ktrans parametric map. Voxel-wise determined Ktrans values are color encoded from 0 to 0.16 min−1. Highest
Ktrans values (white arrows) were observed at the outer rim of the carotid plaque.

No positive IHC stains of PIMO or HIF-1α/macrophage were found in the collected carotid
endarterectomy specimen, and the results could be treated as a negative control. However, we were
able to co-localize HIF-1α and CD68 using an ex vivo CEA specimen from a different study in
which the patient was not administered with PIMO (Fig. 35), suggesting the presence of hypoxic
macrophages in human carotid atherosclerosis.

73

Figure 35 IHC results of a CEA specimen from a patient who did not receive PIMO. H&E staining shows white blood
cell present in the deep intima of the plaque specimen. CD68 (identifying macrophages) and HIF-1α (identifying
hypoxic cells) are co-localized as shown in the co-registered image (top line, middle), and the zoomed in figure (top
row, middle and right) with the focus of interest in the red square. The zoomed in figures of individual stains of CD68,
HIF-1α and nulceus are displayed in the bottom row.

3.3.3
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Cu-ATSM patient study: discussion

In this pilot clinical trial, we were able to obtain good quality analyzable 64Cu-ATSM PET/MR
imaging data sets from 6 asymptomatic patients with carotid atherosclerosis. A 2-fold target-tobackground SUV ratio was observed in the patients with 64Cu-ATSM uptake in carotid plaques
and/or vertebral plaques. IHC staining with PIMO and HIF-1α were each negative in the carotid
endarterectomy specimen we were able to obtain from one of our patients with PET/MR imaging.
This result is expected given that this CEA specimen was obtained from a patient (patient #1)
without
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Cu-ATSM carotid uptake on PET imaging. The team will continue to recruit more

patients upon receipt of additional funding in an attempt to collect more data to reach statistically
significant conclusions.
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DCE-MR imaging performed on two of the patients allowed study of the microcirculation of
carotid plaques (158). The high rate of oxygen consumption by plaque macrophages causes
hypoxia within the plaque, which triggers the increase of plaque microvasculature (26). Abundant
microvasculature has been identified as an important aspect contributing to plaque vulnerability
(159, 160). Although the microvasculature in plaques are very small (up to ∼100 µm in diameter),
the microvessel density and permeability are able to be determined noninvasively by DCE-MRI
(161-164). In recent years, a number of studies have applied DCE-MRI to study atherosclerotic
plaque microvasculature in animals (165-167) and patients (168-172). Kerwin and colleagues
(161-163) performed several DCE-MRI studies in carotid atherosclerotic plaques and showed
correlations between Ktrans and microvessel density and macrophage content. A typical DCE-MRI
experiment to study atherosclerotic plaque microvasculature consists of repeated imaging with a
rapid T1-weighted sequence to measure changes in signal intensity as a bolus of low molecular
weight non-specific Gadolinium-based contrast material is intravenously injected and diffuses into
the tissue. The distribution of contrast medium results in signal enhancement of the blood vessel
lumen, vessel wall due to leakage of the contrast medium through damaged endothelial, and other
tissues, such as skeletal muscle (149). The signal enhancement in the vessel wall depends on flow,
microvascular density, the ability of the contrast medium to leak from the microvasculature into
the extravascular extracellular space, and reflux. After analysis of the resulting DCE-MR images,
pharmacokinetic parameters that are related to the local leaky plaque microvasculature can be
calculated.
The quantification of contrast medium distribution over a tissue of interest can be assessed by
pharmacokinetic modeling, with the main advantage of deriving parameters of the in vivo physical
quantities of the amount, flow, and leakiness of the microvasculature (173). A number of
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quantitative DCE-MRI models have been proposed in the evaluation of atherosclerotic plaque
microvasculature (Table 3). These pharmacokinetic models all describe the relationship between
the concentration of the (extracellular) contrast medium in the blood plasma (Cp) and the
extracellular extravascular space (Ce) according to the two-compartment model (Fig. 32) and using
the parameters Ktrans, and/or ve and/or vp. Ktrans, the transfer constant of contrast medium from plasma
to the tissue compartment, plays as an indicator of blood supply and vessel permeability within the
atherosclerotic tissue. The parameters ve and vp represent the extravascular extracellular space and
the plasma fractional volume, respectively (Table 4). The modified/extended Tofts model is a
commonly employed analytical solution for the two-compartment model, estimating all three
pharmacokinetic parameters (Ktrans, ve and vp) (156, 174). The original Tofts model, which was
proposed for the study of multiple sclerosis (175), does not take vascular contribution into account
(i.e., vp is assumed to be negligible). The Patlak model assumes that reflux, i.e., transfer of contrast
medium from the tissue compartment back to the blood plasma (Ktrans/ve), is negligible (176). The
extended graphical model was introduced as an intermediate solution between the modified Tofts
and the Patlak model (177). This model uses the first-order term of a Taylor series from the
modified Tofts model to estimate ve.
The Patlak model chosen in our study to quantified contrast agent dynamics for DCE-MRI was
found to be most suited for describing carotid plaque enhancement among these four
pharmacokinetic models in terms of reproducibility, fit error, parameter uncertainty, and
correlation with histology of carotid plaque (178). The Parker formula applied to estimate Cp uses
a mixture of two Gaussian functions that was able describe the first and second pass peak of
contrast material. The vascular input function (VIF) in this formula was created from the DECMR images of each patient. However, a generalized VIF, which is obtained from a separate study
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cohort where acquisition is performed with a higher temporal resolution and a lower spatial
resolution (173), is the most commonly chosen method in clinical studies of atherosclerotic plaque
microvasculature. Moreover, there are a lot of undermined parameters in the Parker formula which
are subject to estimation on a case-by-case basis.
We applied a slower injection rate of contrast agent (0.5 ml/s). This is different from DCE-MRI
studies of brain and tumor perfusion that mostly use a contrast medium injection rate of 2 ml/s
(typically 0.1 mmol/kg) because a high injection rate is most beneficial for high Ktrans values (>
0.2 min−1) (179) while typically the mean Ktrans values are below 0.15 min−1 (180) within the
atherosclerotic lesion, which is consistent with our own measurement.
Table 3 Overview of pharmacokinetic two-compartment model and model solutions (173).


Mathematic Description
Two-compartment model

𝑑𝐶𝑒 (𝑡)
𝑑𝑡

=

𝐾𝑡𝑟𝑎𝑛𝑠
𝑉𝑒

Parameters

[𝐶𝑝 (𝑡) − 𝐶𝑒 (𝑡)]

𝐶𝑡 (𝑡) = 𝑣𝑝 𝐶𝑝 (𝑡) + 𝑣𝑒 𝐶𝑒 (𝑡)
Model solutions
𝐾𝑡𝑟𝑎𝑛𝑠
−(
)(𝑡−𝜏)
𝑣𝑒

Tofts (156, 174)

𝐶𝑡 (𝑡) = 𝐾 𝑡𝑟𝑎𝑛𝑠 ∫0 𝐶𝑝 (𝜏) ∙ 𝑒

Modified/extended Tofts (156, 174)

𝐶𝑡 (𝑡) = 𝑣𝑝 𝐶𝑝 (t) + 𝐾 𝑡𝑟𝑎𝑛𝑠 ∫0 𝐶𝑝 (𝜏) ∙ 𝑒

Patlak (176)

𝐶𝑡 (𝑡) = 𝑣𝑝 𝐶𝑝 (𝑡) + 𝐾𝑡𝑟𝑎𝑛𝑠 ∫0 𝐶𝑝 (𝜏) 𝑑𝜏

Extended Graphical (177)

𝐶𝑡 (𝑡) = 𝑣𝑝 𝐶𝑝 (t) + 𝐾 𝑡𝑟𝑎𝑛𝑠 ∫0 𝐶𝑝 (𝜏)𝑑𝜏 −

𝑡

𝑡

𝐾 𝑡𝑟𝑎𝑛𝑠
𝑣𝑒

2

𝑡 𝜏1
∫0 ∫0 𝐶𝑝 (𝜏2 )𝑑𝜏2 𝑑𝜏1
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𝑑𝜏
𝐾𝑡𝑟𝑎𝑛𝑠
)(𝑡−𝜏)
𝑣𝑒

−(

𝑑𝜏

Ktrans

ve

×

×

×

×

𝑡

×

𝑡

×

vp

×
×

×

×

Table 4 Description of the parameters used in DCE-MRI pharmacokinetic models (173).


Quantity
Cp(t)
Ce(t)

Definition

Unit

Blood plasma concentration of Gd-DTPA as a function of
HU or mM
time (Jugular vein was chosen )
Extracellular extravascular space (EES) concentration of
HU or mM
Gd-DTPA as a function of time

Ct(t)

Tissue concentration of Gd-DTPA as a function of time

HU or mM

Ktrans

Transfer constant from the blood plasma into the EES

mL/g/min

Kep

Transfer constant from the EES back to the blood plasma

1/min

t

Onset time of arterial contrast uptake

sec

vp

Blood plasma volume per unit of tissue

mL/g

ve

Total EES volume (ve = Ktrans/Kep) per unit of tissue

mL/g

The most widely used DCE-MRI pharmacokinetic parameter is the transfer constant Ktrans that
describes the relationship between the arterial input function (Cp) and increasing contrast
concentration in tissue (Ct). Put simply, Ktrans provides a quantitative measurement of enhancement
and is limited by either the vascular blood flow or permeability (158). As mentioned in Chapter 2,
in atherosclerotic plaques, hypoxia-induced increases in VEGF may contribute to the development
of unstable lesions by promoting angiogenesis (26). Hypoxia continually up-regulate this HIF-1regulated angiogenic factor, VEGF, to meet metabolic demands; however, the angiogenic vessels
are structurally defective and fail to support adequate blood supply that further worsens local
hypoxia, ensuring a vicious cycle (59). The overexpression of VEGF leads to leaky vasculature
and high vessel permeability, facilitating both intravasation and extravastion of Gd-DTPA contrast
agent. Significant positive correlations were found between Ktrans and the endothelial microvessel
content determined on histologic studies (149). Therefore, the (leakage) volume transfer constant
Ktrans used for quantifying neovascularization, together with the
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Cu-ATSM image to identify

hypoxic plaques, is a promising method to diagnose and predict patients with vulnerable plaques
who might be benefit from taking the risk of more aggressive treatments for carotid atherosclerosis
(e.g. carotid endarterectomy). Truijman et al (172) demonstrated that there is a weak but significant
positive correlation between inflammation on 18F-FDG PET/CT and neovascularization (Ktrans) as
assessed with DCE-MRI. Wang et al further showed that the correlation between 18F-FDG PET
uptake and Ktrans varied with clinical conditions, pointing to a complex interplay between
macrophages and neovessels under different pathophysiological conditions. Nevertheless, as the
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Cu-ATSM PET and DCE-MR imaging modalities are not interchangeable, the combination may

increase the chance to predict the vulnerability of plaques.
There are some limitations in our 64Cu-ATSM PET/MR imaging study of carotid atherosclerotic
patients. First, it was difficult to recruit enough patients for this clinical trial. Although we initially
recruited up to 20 patients, only 7 of them eventually agreed to complete the scanning, of whom 6
had acceptable image quality, two performed DCE-MRI scanning, and only one underwent carotid
endarterectomy (CEA; different from the ones who underwent DEC-MRI), because only
symptomatic patients with severe ipsilateral stenosis is more likely to have developed advanced
atherosclerosis plaques and may benefit the most from CEA (181). Therefore, we were unable to
collect enough data and from either the PET/MR images or the IHC stains to demonstrate our
hypothesis on a statistically significant level.
Future plans for the remainder of the research team is to continue to recruit patients with carotid
atherosclerosis scheduled for carotid endarterectomy into this trial. , We will measure and compare
the SUVs of plaques and plaque-to-background SUV ratios on
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Cu-ATSM PET images of the

patients with and without atherosclerosis visualized on MRI. Common carotid images from the
mandibular angle to the base of the neck will be presented to a single blinded reader who will
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grade transverse images of the carotids at each 4 mm interval for the presence or absence of
atherosclerosis. If atherosclerosis is present on that image, the reader will grade the presence or
absence of lipid core and presence or absence of hemorrhage and correlate the findings to 64CuATSM uptake.
IHC staining serve as a “gold standard” to support any of our conclusions regarding 64Cu-ATSM
uptake and Ktrans values about human carotid atherosclerosis. We will need to collect at least 3
carotid endarterectomy specimens that all show 64Cu-ATSM uptake as well as positive PIMO and
macrophage staining results. The correlation between Ktrans values with histologic findings will be
investigated as well once we have enough patients undertake DEC-MR imaging. For further
studies, the CEA specimen will also be treated with HIF-2α, VEGF, hematoxylin and eosin (H&E)
and/or Verhoeff Van Gieson (VVG) stains. The immunoreactivity for hypoxia in the plaques as
well as HIF-1α, HIF-2α, VEGF and CD68 will be scored by one observer, a histopathologist, on a
scale from 0-3, with 0 = none; 1= mild; 2 = moderate and 3 = extensive. H&E and VVG-stained
specimens will be used to grade plaque severity using the American Heart Association (AHA)
classification for atherosclerosis (109). Sections will be graded by a separate observer, a vascular
biologist, blinded to the IHC. Briefly, AHA grades for atherosclerosis disease progression are I)
intimal thickening, II) fatty streak, III) preatheroma, IV) atheroma, V) fibroatheroma, and IV)
complicated lesion due to fissure, hemorrhage, or thrombus. Then we will be able to investigate
the uptake of 64Cu-ATSM on the plaque component and severity level.
The ultimate goal of this clinical trial is to make 64Cu-ATSM PET/MR imaging an FDA approved
standard of care for diagnosing vulnerable carotid atherosclerosis, in order to aid physicians in
determining whether the patient will benefit from the more risky carotid endarterectomy surgery.
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Chapter 4: Improving 64Cu-ATSM PET
image quality
In this chapter, we will discuss the strategies we have employed to improve the 64Cu-ATSM PET
image quality via correction for partial volume effects using Siemens HD PET software during
image reconstruction and post-reconstruction image processing techniques. We also evaluated the
accuracy of attenuation correction effects from the carotid surface coils and the thermoplastic
holder.

4.1 Correction for partial volume effects
The partial volume effects (PVE) originally referred to the loss of signal for structures partially
occupying the PSF of the scanner (142, 182). PVEs now usually incorporate both spill-out and
spill-in effects. The loss of signal in the object will be distributed across adjacent voxels, which
are considered outside the object, resulting in increase in signal in these voxels (spill-out effects).
The reciprocal effect of poor spatial resolution is the contamination of signal from neighboring
tissue or spill-in effects (182, 183). PVEs in MR or CT are typically meant by blurred anatomical
details smaller than the chosen pixel size, while the dominant PVE cause in PET usually refers to
that anatomical details smaller than 3 times the FWHM of the PSF appear smeared out. In
quantitative studies of PET images, PVEs introduce distortions both in the targeted region and in
adjacent tissue, depending on tracer distribution (184, 185). As a result both the magnitude and the
shape of the time activity curves (TACs) can be changed. An error of 50% was observed in
estimated rate constants for metabolism and transfer of tracer between compartments (186).
In terms of PVEs in human carotid atherosclerosis PET imaging, the diameter of carotid arteries
are on average 6 mm with atherosclerotic wall thickness of a few millimeters (187), we can expect
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important PVE in the measurement accumulated

64

Cu-ATSM uptake to a particular plaque

component (lipid/necrotic pool, fibrous cap, blood vessel wall, etc.).
In this section, I will discuss my work on partial volume effects correction (PVC) through applying
the HD PET reconstruction software and implementing PVC techniques in the image space post
image reconstruction.

4.1.1 Partial volume effects in PET
It is understood that the physical size width of the detection element (also known as crystal size)
plays an important role in determining the spatial resolution in positron emission tomography
(PET), while the combined contribution from acollinearity, positron range, decoding errors in the
detector modules, and penetration into the detector ring often combine to be of similar size (188190) (Fig. 36). The sampling geometry, which is also related to the crystal size, and statistical
noise further degrade the effective resolution (190).

Figure 36 Diagrammatical and quantitative interpretation of the contributions to spatial resolution in PET. (Adapted
from "Fundamental limits of spatial resolution in PET," by William W. Moses, 2010, NIMA_4th International
Conference on Imaging techniques in Subatomic Physics, Astrophysics, Medicine, Biology and Industry, Volume
648(1), p S236-S240. Copyright (2010) by title of publisher.)
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The empirical formula for the reconstructed spatial resolution 𝛤 for a point source located at
radius r from the center of the camera ring is given by

𝛤 = 1.25√(𝑑/2)2 + 𝑠 2 + (0.0044𝑅)2 + 𝑏 2 +

(12.5𝑟)2
𝑟 2 +𝑅 2

,

(4)

where d is the crystal width, s is the positron range, b is the crystal decoding error factor (d/3 for
detector designs that utilize optical decoding, zero otherwise) (190), and R is the detector ring
radius. The factors in the quadrature sum in the above equation, going from left to right, are due
to the detector size, the positron range, acollinearity, decoding error, and penetration, and the
multiplicative factor of 1.25 is due to the reconstruction algorithm (190).
The “fundamental” effects can be reduced to detector width, positron range, and acollinearity
through careful camera design. Thus, 𝛤 for this “ultimate” design is given by:
2

𝑑
𝛤 = √( 2 ) + 𝑠 2 + (0.0044𝑅)2 (𝑚𝑚 𝑓𝑤ℎ𝑚),

(5)

where d is the crystal width, s is the positron range, and R is the detector ring radius.
Accordingly, given the minimum mean positron range among the common positron emitting
isotopes is 0.6 mm for 18F, the fundamental limit for clinical and pre-clinical PET cameras will be
1.83mm FWHM and 0.67 mm FWHM, respectively. However, practically clinical and pre-clinical
PET cameras can achieve 2.36 mm FWHM and 0.83 mm FWHM reconstructed spatial resolution,
respectively (190).
The spatial resolution is usually characterized by the PSF, which essentially corresponds to the
system response in accounting for all the “fundamental” effects to a point source. In general the
PSF in PET images is spatially variant. The distribution of values depends on the location of the
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source in the FOV of the scanner. However, it is reasonable to assume that the PSF is positioninvariant (191) in the central portion of the scanner (~15-20 cm diameter). It is widely accepted
that PET PSF can be approximated as an anisotropic 3D Gaussian function that is written as:
ℎ(𝑟) =

1
3
(2𝜋)2 𝜎𝑥 𝜎𝑦 𝜎𝑧

1 𝑥2

𝑦2

𝑧2

𝑥

𝑦

𝑧

𝑒𝑥𝑝 (− 2 ⌈𝜎2 + 𝜎2 + 𝜎2 ⌉),

(6)

where 𝜎 = [𝜎𝑥 , 𝜎𝑦 , 𝜎𝑧 ] is the standard deviation in the transverse, radial and axial directions. The
PSF can be measured by fitting the Gaussian function of the PET image of a point radioactivity,
and FWHM is related to the standard deviation as 𝜎 = 𝐹𝑊𝐻𝑀/2√2 ln 2.
The reconstructed PET image can be viewed as a convolution of the true activity distribution with
the PSF. The Fourier transform of the PSF, known as the modulation transfer function (MTF),
contains the same information as the PSF. Therefore, a PET image can be described in the
frequency domain as the product of the Fourier transform of the true activity distribution and the
MTF of the system. This means that image components corresponding to mid-range frequencies,
despite attenuation, may still be present in the data and could in principle be restored by an inverse
filtering operation. Nevertheless, image components at higher frequencies will not be sufficiently
sampled by the 4 mm-width PET detector crystals and therefore the MTF will be essentially zero.
These image components will not be measured adequately and attempts to restore them usually
lead to noise-amplification or image artifacts. Pre-clinical PET systems improves this limitation
of clinical PET scanners with the use of smaller PET detector crystals and smaller ring radius.
An important intrinsic limitation in the PET application for the accuracy of quantitative studies is
represented by the relatively poor spatial resolution of the scanner – leading to partial volume
effects. The direct consequence of limited resolution is the loss of spectral signal for structures
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partially occupying the PSF of the scanner (142, 192). If the dimensions of object or structures to
be imaged is less than 3-4 times the instrument resolution (FWHW) of the imaging system, the
resultant activity will be underestimated. Depression of apparent isotope concentration in an image
for objects equal in size to the FWHM can be significant (144, 183, 193).
Once the PSF is known, it can be used to compensate for the PVEs, basically based on two different
approaches: during reconstruction (194-196), in which approach the spatial resolution degradation
is considered to originate at raw data level and deconvolution is achieved by incorporating PSF in
the system matrix or equivalently by blurring each image estimate prior to forward projection
during iterative image reconstruction (see section 4.1.2) or in the image space (197, 198), which
assumes an effective resolution degradation happening at the image level (see section 4.1.3). Both
methods can only approximate the actual resolution model due to the complexity of superposing
several different effects. All PVC methods have limitations and can lead to noise-amplification or
image artifacts, such as Gibbs artifacts (ringing in the vicinity of sharp boundaries). Because of
the ill-conditioned nature of the restoration problem, some form of regularization is needed.
Multiple regularization techniques are achieved by incorporating anatomical information and
tissue homogeneity constraints. For example, Strul and Bendriem used an anatomically based PVC
method that utilize structural information from other imaging modalities as a priori information to
stabilize the solution (199). Wang and Fei (200) further developed an image-guided, voxel-based
PVC method that correct PET images by iterative deconvolution withy an edge preserving
smoothing constraint regularization. The constraint can restore discontinuities extracted from
coregistered MR images but maintains the smoothness in radioactivity distribution.
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4.1.2 PVC during image reconstruction
The PET list-mode data acquired from the Siemens PET/MR scanner can be reconstructed using
the HD (High Definition) PET that relies on Point Spread Function corrected ordinary Poisson
Ordered Subset Expectation Maximization (PSF-OSEM) reconstruction algorithm that
incorporates a spatially invariant effective, image based, PSF in the reconstruction algorithm. HD
has recently been introduced for the Siemens mMR. In summary, using measured PSFs, HD PET
reduces blurring and distortion in the final image, therefore delivering superior detection of small
lesions. It provides twice the signal-to-noise ratio (SNR) and near uniform spatial resolution
throughout the FOV with 2 mm spatial resolution improvement (201), as compared to the usual >
4.5 mm spatial resolution in Siemens Biograph mMR PET/MR scanner (202).

4.1.2.1 PVC during image reconstruction: introduction
Generally, PET image reconstruction methods are divided to analytic methods, e.g. Filtered BackProjection (FBP), and iterative methods, e.g. OSEM and maximum likelihood expectation
maximization (ML-EM). FBP is a back-projected image after filtering of the sinogram. OSEM is
developed for improving the disadvantages of ML-EM method (203), such as its long calculation
time. The quality of OSEM image is superior to that of FBP images because iterative approaches
can potentially increase the accuracy of images compared to analytic method although noise
increases with an increasing number of iterations (204-206). Post-reconstruction imaging filtering
methods, such as the popular Gaussian smoothing filtering, are used to reduced background noise
and improve signal-to-noise ratio (SNR) of image with better contrast (207). However, Gaussian
filtering also results in image distortion (203), depending on the size of filter. It will be necessary
to compare various combinations of reconstruction algorithms with number of iterations and
Gaussian filter size to investigate the optimal effective spatial resolution so as to make the most
accurately quantitative analysis with the PET images.
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Provided that the detection of each decay event by the PET system (photon pairs produced through
annihilation of positrons emitted from the PET tracer) is independent and can be modelled as a
Bernoulli process, the sinogram data can then be view as a collection of independent Poisson
random variables and estimated by ML function that maximizes the probability of the observed
data assuming no prior statistical model on the tracer distribution (208).
̅ = {𝑦̅𝑖, 𝑖 = 1, … , 𝑀} denote mean of the data, where M is the number of detector bins in the
Let 𝒚
̅ and the unknown tracer distribution 𝑓(𝑥) is described as
PET system. The relationship between 𝒚
follows (208):
𝑦̅𝑖, = 𝐸[𝑦𝑖 ] = ∫ 𝑓(𝑥)𝑐(𝑖, 𝑥) d𝑥 + 𝑟𝑖 + 𝑠𝑖 ,

𝑖 = 1, … , 𝑀

(7)

where 𝑐(𝑖, 𝑥) is the detection response function for the ith measurement or line of response (LOR),
r and s represent the expectations of random events and scattered events, respectively.
Equation (7) can be approximated as the affine transform as follows (208):
̅ = 𝐸[𝒚] = 𝑷𝒇 + 𝒓 + 𝒔,
𝒚

(8)

where 𝑷 ∈ ℝ𝑀×𝑁 is the projection or system matrix. The element, 𝑝𝑖𝑗 = ∫ 𝑐(𝑖, 𝑥)𝜙𝑗 (𝑥)d𝑥, in
which 𝜙𝑗 (𝑥) denotes the jth voxel basis function, is the average probability of detecting an
emission from voxel j at LOR i.
The conditional probability, or likelihood function, for the measured data, 𝒚 = {𝑦𝑖, 𝑖 = 1, … , 𝑀},
given the tracer distribution f, is expressed as the independent Poisson distribution (208):

𝑝(𝒚|𝒇) = ∏𝑖 𝑒

̅𝑦̅̅̅𝑦𝑖
−𝑦̅𝑖 𝑖
𝑦𝑖 !

.

(9)
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Since log is a monotonic function, the ML estimates of 𝒇 can be computed by maximizing either
Equation (9) or the log of the likelihood function, defined as (208):
𝐿(𝒚|𝒇) = ∑𝑀
̅)
̅𝑖 − log(𝑦̅!)
𝑖 −𝑦
𝑖 .
𝑖=1 𝑦𝑖 log(𝑦

(10)

The solution of the ML estimate is expressed as (209, 210):
𝑓𝑗𝑘+1 = 𝑓𝑗𝑘 ∙ ∑

1

𝑖 𝑝𝑖,𝑗

∑𝑖 [𝑝𝑖,𝑗 ∙

𝑦𝑖

∑𝑖 𝑝𝑖,𝑗 ∙𝑓𝑗𝑘 +𝑟𝑖 +𝑠𝑖

],

(11)

where 𝑓𝑗𝑘+1 and 𝑓𝑗𝑘 are the updated and old images voxel j.
When EM iterative image reconstruction is accelerated through updating the image using a subset
of angles, it is then called ordered subset expectation–maximization (OSEM) algorithm or
ordinary Poisson (OP)-OSEM algorithm (211). If system matrix is derived from point source
measurement and the point spread function is incorporated into the system matrix for 3D PET
reconstruction, OP-OSEM becomes PSF-OSEM (196).
Many statistically based 3D reconstruction methods are based on the EM or OSEM algorithm
(212). Both approaches can exhibit high-variance behavior at high iteration numbers and are
regularized through early termination of the algorithm or by subsequent smoothing of the
reconstructed images (191, 212). A maximum a posteriori (MAP) formulation, which is used in
small animal PET scanner for image reconstruction, controls the variance and resolution of the
reconstruction through the regularizing influence of a smoothness prior (191). Therefore the MAP
methods allow solutions with a low degree of variability between adjacent voxels, and prevent the
instabilities at higher iterations encountered using EM and OSEM (212). The MAP solution can
be computed using a 3D extension of the pre-conditioned conjugate gradient algorithm (213).
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4.1.2.2 Evaluation of effective spatial resolution: materials and methods
We used a phantom to evaluate the effective spatial resolution of HD PET (PSF-OSEM
reconstruction algorithm), ordinary Poisson OSEM (OP-OSEM) reconstruction algorithm and the
FBP reconstruction algorithm which was used as reference.
Thin-wall hot-spot spheres (diameter = 7.7, 9.8, 15.8 mm) in a cylindrical phantom that mimicked
neck were filled with 6.3-times higher radioactivity (18F-FDG) concentration than background
(Fig. 37). The total volume of the spheres and the total volume outside the spheres in the cylindrical
phantom were measured by weighting the correspond parts with and without water filling. Their
activity ratio was calculate by multiplying their pseudo-concentrations (6.3 and 1, respective) by
their measured volume, and the total activity (1 mCi

18

F) will be distributed accordingly. After

mixing the activity with the measured volume of water, the diluted activity in correct radioactivity
concentrations will be injected into the spheres and cylindrical phantom by a syringe.
The ratio radioactivity 6.3 was based on the average aortic arch-to-background SUV ratio of the
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Cu-ATSM ApoE-/- mouse study. Circular ROIs were used to measure the spatial resolution.

Static PET/CT scanning was performed. Three PET image reconstruction schemes were performed
using Siemens e7-tools: OP–OSEM), PSF–OSEM and FBP. The e7-tools is a research package
provided by Siemens that allow the processing and reconstruction of Siemens PET emission data.
It is identical to the reconstruction software on the Siemens mMR console. The reconstructed PET
images with a dimension of 256×256×127 and a voxel size of 0.7×0.7×2.03 mm was interpolated
to a dimension of 256×256×256 and a voxel size of 0.7×0.7×1.01.
For both OP-OSEM and PSF-OSEM, 16 subsets, 2-8 iterations, and 1-6 mm post-reconstruction
Gaussian smoothing filtering was used.
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Figure 37 Thin-wall hot-spot spheres (diameter = 7.7, 9.8, 15.8 mm) placed in a cylindrical phantom of ~10 cm in
diameter.

The object function, O, was denoted by a digital mask created on MATLAB based on caliper’s
measurement of the phantom dimensions and the CT images. A digital representation of the
phantom was created for which all pixels within the ROIs were assigned a value 6.3, elsewhere
within the phantom 1, and 0 outside the phantom. The digital image was constructed with the same
matrix size and voxel size as the object function as the CT image. The measured image I(x,y) is
related to the object image O(x,y) by the PSF with:
𝐼(𝑥, 𝑦) = 𝑂(𝑥, 𝑦)⨂𝑃𝑆𝐹(𝑥, 𝑦),

(12)

where ⨂ indicates 2-dimentional convolution.
To measure PSF, each slice of the object and original image volumes was transformed by 2D
Fourier transform, and data from corresponding slices of I was divided by O in the Fourier domain.
The resulting data was inverse Fourier transformed to result in a PSF in physical space:
𝐹[𝐼]

𝑃𝑆𝐹(𝑥, 𝑦) = 𝐹 −1 [𝐹[𝑂]],

(13)
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where F indicates the 2D Fourier transform and F-1 indicates the inverse 2D Fourier transforms.
Spatial resolution (FWHM) was characterized by fitting a 2D Gaussian function or 1D Gaussian
funciton in x and y profiles to the the PSF image. The method was made particularly robust with
respect ot noise by averaging the PSF images for all slices before performing the Gaussian fit. This
approach not only reduced statistical noise but also effectively suppressed parallel line artifacts
that occationally apeared in the PSF images due to dividing noisy data in Fourier space (214).
In order to validate the measurement PSF of the PET scanner, we created a simulated PET image
by convolving the object function with a 3D Gaussian function using the measured FWHM and
compared the recovery coefficients (RC) of hot spheres in original PET image with simulated PET
images. RC was calculted by the following equation:

RC (recovery coefficent) =

Measured hot sphere – Measured back ground
True hot sphere – True background

.

(14)

4.1.2.3 Evaluation of effective spatial resolution: results
The quality to OSEM reconstructed PET images are superiors to that of FBP reconstructed PET
images. The PSF-OSEM (HD PET) algorithm reconstructed PET images had improved spatial
resolution, higher contrast and lower noise compared with the corresponding images obtained
using the standard OP-OSEM algorithm and FBP algorithm (Fig. 38). PSF-OSEM performed a
little better than OP-OSEM in term of its spatial resolution at the same number of iterations and
Gaussian smoothing level. For both OSEM algorithms, the spatial resolution was improved with
respect to increasing number of iterations and decreasing size of Gaussian smoothing filter. The
optimal resolution was achieved with minimal post-filtering and maximal number of iterations.
The measured spatial resolution of the PET scanner in Siemens PET/MR system with HD PET
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reconstruction was consistent with literature (~4.3mm), but not as good as the valued claimed by
the manufacturer (~3mm) (Fig. 39)

Figure 38 PET images reconstructioned by PSF-OSEM, OP-OSEM and FBP algorithms, the cerresponding averaged
PSF images, and profiles through the PSF images showing the results of 1D Gaussian fits in x and y directions (red
line).

Figure 39 FWHMs of the PET images reconstructioned by PSF-OSEM and OP-OSEM algorithms using 2-8 iterations
and 1-6 mm Gaussian smooting filtering. The smallest FWHM (best resolution) was observed at 8 iterations and 1
mm Gaussian smooting filtering for both reconstruction algorithms.
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With acceptable differences, the signal intensity profile across spheres and recovery coefficients
of spheres in the Gaussian kernel filtered digital mask matched with the PSF-OSEM and OPOSEM reconstructed PET images, especially at higher iteration numbers, demonstrating that the
results of this PET spatial resolution measurement is reasonable (Fig. 40, Fig. 41). The match is
greater on smaller spheres using the PSF-OSEM reconstruction algorithm, while is greater on
larger spheres using the OP-OSEM reconstruction algorithm. However, increasing the number of
iterations resulted in longer processing time and, more importantly, increased noise. The balance
between an optimal effective image resolution and an acceptable noise level was determined by
practice.
We then investigated the relationship between image noise and number of iterations using PSFOSEM reconstruction algorithm with different Gaussian smoothing filters. The noise level of
image was calculated as the variance of the background. The plot demonstrated that image noise
level is increased with respect to increased number of iterations and reduced Gaussian filtering
size (Fig. 42). As a consequence, the spatial resolution of the reconstructed PET image and the
recovery coefficients of the spherical objects were improved with increasing noise level (Fig. 43).
However, at 8 iterations, the image quality has not been dramatically deteriorated by the noise, so
can we will be benefit from selecting this number of iterations to achieve a higher effective spatial
resolution.
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(A)

(B)

Figure 40 The transverse veiws of all three spheres on the 3D digital mask, (A) PSF-OSEM and (B) OP-OSEM
reconstructed PET images using the combination of the reconstruction parameters that provided the best spatial
resolution as measured, and the 3D Gaussian kernal filtered digital mask using the measured PSF of the
correspongding reconstructed PET image. The signal intensity profile across the small and medium spheres on the
PET image and Gaussian kernel filtered digital mask generally overlapped with acceptable differences.
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(A)

(B)

Figure 41 The recovery coefficients of the three spheres measured on the (A) PSF-OSEM and (B) OP-OSEM
reconstructed PET images with various number of iterations and Gaussian smoothing filtering levels, and the 3D
Gaussian kernal convoled digital mask using the measured PSF of the correspongding reconstructed PET image. The
recovery coefficients of the PET image and Gaussian kernel filtered digital mask generally matched with acceptable
differences, especially at higher iterations.
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Figure 42 Relationship between image noise and number of iterations in PSF-OSEM reconstructed PET images using
different Gaussian filtering.

Figure 43 Relationship between (A) resolution (FWHM) and image noise, and (B) recovery coefficients of spheres
in different sizes and noise in PSF-OSEM reconstructed PET images using 2 mm Gaussian filtering.

96

We investigated the effects of sphere-to-background radioactivity (18F-FDG) ratios (contrast
ratios), we compared the recovery coefficients of the thin-wall hot spheres with different sizes
imaged with the Siemens small animal PET scanner and reconstructed using the MAP algorithm
with the same Gaussian smoothing filtering but different number of iterations. It shows that when
the contrast ratio is high enough, say greater than 6-to-1, the recovery coefficients are general the
same for increasing contrast ratios. In high contrast ratios, the recovery of larger spheres (diameter
> 4.8 mm) are equal for both 3 and 8 iterations, but the recovery coefficients of smaller spheres
(diameter < 2.98 mm) using 8 iterations is higher than that using 3 iterations (Fig. 44).

Figure 44 Recovery coefficients of spheres with different sizes versus sphere-to-background contrast ratios. Listmode PET data was acquired from 18F-FDG PET imaging using the Siemens small animal PET scanner, and
reconstructed using the PSF-OSEM algorithms with 1 mm Gaussian smoothing filtering, 24 subsets, and (A) 3
iterations, or (B) 8 iterations.
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4.1.2.4 PVC during image reconstruction: discussion
The PSF-OSEM reconstruction algorithm that accounts for the PSF during image reconstruction
works to improve the spatial resolution of PET images as compared to the OP-OSEM algorithm,
however it did not achieve the manufacturer claimed resolution of ~3 mm. This might be attributed
to that the PSF-OSEM algorithm can only partially corrected for PVEs, or the 3 mm optimal
resolution was measured from a point source by the manufacturer, but we used distributed objects.
Since the human carotid atherosclerosis are on the dimension of a few mm, they would still be
dramatically affected by partial volume effects and further post-reconstruction partial volume
correction might help.
Due to the loss of high frequency information in the object and the nonlinear nature of the
reconstruction, PVEs are at best reduced in magnitude provided a sufficient number of iterations
are performed, but quantitative recovery is not complete. Better results could be achieved with
reconstruction algorithms involving anatomical information assuming the control of noise and
inclusion of edges between functional structures. However, although visually these techniques can
produce very striking image contrast, there is rather limited reference to the effectiveness of these
techniques in achieving quantitative PVC (191).
In iterative image reconstructions increasing the number of iterations requires more time.
Moreover, along with image resolution, noise also increases with an increasing number of
iterations, which is also established in literature (205, 206). At high iterations, with or without
filtering, noise blows up and the image will be useless. Unfortunately, the relative trade-offs for
both visualization and measurement tasks are unclear and the selection of the number of iteration
is a practical problem in every laboratory using PET (203). Since the incremental changes in spatial
resolution is insignificant beyond 8 iterations, and the noise at this number of iterations does not
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significantly affect the image visualization, we are likely to choose 8 iteration and 1 mm Gaussian
smoothing filtering for

64

Cu-ATSM image reconstruction using PSF-OSEM algorithms for best

effective spatial resolution.

4.1.3 PVC via post-reconstruction image processing
Alternatively, PVC can be performed by image restoration in image space. Image restoration is a
wide field of study which has been applied to numerous applications. Numerous approach and
variant of those approaches exists in the literature. We investigated 4 image based PVC methods.
We first applied these technique to a digital simulated phantom, then to PET images of a
homemade phantom mimicking human carotid plaque and to clinical human carotid plaque 64CuATSM PET/MR images. The PVC approaches studies included the region-based geometric
transfer matrix (GTM) method, the voxel-based iterative deconvolution method (RichardsonLucy), as well as regularized iterative deconvolution methods (RL deconvolution with total
variation regularization and anatomy image (MR, CT, etc.)-guided, image restoration.

4.1.3.1 Image-based PVC methods
I.

Region-based geometric transfer matrix (GTM) method

The GTM method, initially introduced by Rousset et al. (186), is based on the principles of linear
systems and pairwise interaction between identifiable regions containing homogeneous
radioactivity concentration. It is based on the fact that the PET image is the convolution of the
activity distribution present in the FOV by the response function of the PET system in terms of its
PSF. Then the true activity distribution is composed of the linear superposition of substructures of
activity 𝑇𝑖 with mean observed value within 𝑅𝑂𝐼𝑗 :
𝑡𝑗 = ∑𝑁
𝑖=1 𝑤𝑖𝑗 𝑇𝑖 ,

(15)
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where 𝑤𝑖𝑗 represents the contribution of each substructure to any 𝑅𝑂𝐼𝑗 in the image and computed
for each component of nonzero activity to generate the matrix of regional transfer coefficients,
known as the geometric transfer matrix (GTM):
𝑤11
𝑡1
𝑤12
𝑡
[ ⋮2 ] = [
⋮
𝑤
𝑡𝑁
1𝑁

𝑤21
𝑤22
𝑤2𝑁

… 𝑤𝑁1
𝑇1
⋯
⋮
𝑇
] × [ 2 ],
⋱
⋮
⋮
𝑇𝑁
⋯ 𝑤𝑁𝑁

(16)

where the diagonal terms represent tissue self-interaction (regional recovery coefficients) and offdiagonal terms express the fraction of true activity 𝑇𝑖 spilled over from domain 𝐷𝑖 and integrated
in 𝑅𝑂𝐼𝑗 .
The regional values actually observed with PET, 𝑡𝑗 , and the GTM represent a system of linear
equations that can be solved for the true values 𝑇𝑖 .
II.

Richardson-Lucy deconvolution

The Richardson-Lucy (RL) deconvolution named after William Richardson and Leon Lucy (215,
216), is a Bayesian-based derivation of iterative expectation-maximization (EM) algorithm (5, 13)
for recovering a latent image that has been blurred by a known PSF. It’s often chosen for its
simplicity and performance (191).
The RL algorithm is based on the following mathematical image formation model:
𝑖(𝑟) = 𝑃(𝑜(𝑟)⨂ℎ(𝑟)),

(17)
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where r is a three-element vector ([𝑥, 𝑦, 𝑧]𝑇 ) representing a point in a three-dimensional space or
two-element vector ([𝑥, 𝑦]𝑇 ) in two dimensions, 𝑖(𝑟) represent the recorded image represented as
3D array, where each item value corresponds to the intensity of a measured voxel, 𝑜(𝑟) is the
object, ℎ(𝑟) is the PSF, ⨂ denotes convolution operator, 𝑃 represents Poisson noise originating
from counting photons.
The RL algorithm seeks to determine𝑜(𝑟), from the observation 𝑖(𝑟), knowing the PSF ℎ(𝑟), by
maximizing the likelihood distribution with respect to 𝑜(𝑟) (expectation-maximization, or by
minimizing the functional− log 𝑝(𝑖|𝑜), which is equivalent to minimize 𝐽1 (𝑜):
𝐽1 (𝑜) = ∑𝑠(−𝑖(𝑟) log[(𝑜⨂ℎ)(𝑟)] + (𝑜⨂ℎ)(𝑟)),

(18)

and it is equivalent to searching for a zero of the gradient of 𝐽1 (𝑜) which results in solving:
[(𝑜

𝑖(𝑟)
𝑘 ∗ℎ)(𝑟)

] ∗ ℎ(−𝑟) = 1.

(19)

Let 𝑜𝑘 (𝑟) be the estimate of 𝑜(𝑟) at iteration k. Then one iteration of the RL deconvolution is
given by:
𝑜𝑘+1 (𝑟) = {[(𝑜

III.

𝑖(𝑟)
𝑘 ∗ℎ)(𝑟)

] ∗ ℎ(−𝑟)} 𝑜𝑘 (𝑟).

(20)

RL deconvolution with total variation (TV) regularization

RL deconvolution tends to amplify noise, but regularization constraints based on some prior
knowledge on the data can be applied to stabilize the solution. Thus TV regularization is added to
the RL deconvolution to suppress unstable oscillation artifacts while preserving object edges (217).
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This turns out to be a minimization problem of the resultant equation that expresses the model with
maximum likelihood approach and TV regularization:
𝐽1 (𝑜) + 𝐽𝑟𝑒𝑔 (𝑜) = ∑𝑟(−𝑖(𝑟) log[(𝑜 ∗ ℎ)(𝑟)] + (𝑜 ∗ ℎ)(𝑟)) + 𝜆 𝑇𝑉 ∑𝑟|∇𝑜(𝑟)|,

(21)

which is equivalent to solving the following equation:
1−

𝑖
⨂ℎ(−𝑟)
(𝑜⨂ℎ)(𝑟)

∇𝑜(𝑟)

− 𝜆 𝑇𝑉 𝑑𝑖𝑣 (|∇𝑜(𝑟)|) = 0,

(22)

in which the derivative 𝐽𝑟𝑒𝑔 with respect to 𝑜(𝑟) is a nonlinear term:
𝜕
𝐽
𝜕𝑜 𝑟𝑒𝑔

∇𝑜(𝑟)

= −𝜆 𝑇𝑉 𝑑𝑖𝑣(|∇𝑜(𝑟)|).

(23)

Then one iteration of a multiplicative gradient type algorithm (RL-TV deconvolution) is defined
by:
𝑜𝑘+1 (𝑟) = {[(𝑜

𝑖(𝑜)
𝑘 ∗ℎ)(𝑟)

] ∗ ℎ(−𝑟)}

𝑜𝑘 (𝑟)

∇𝑜𝑘(𝑟)
)
|∇𝑜𝑘(𝑟)|

1−𝜆𝑇𝑉 𝑑𝑖𝑣(

,

(24)

where 𝜆 𝑇𝑉 is the regularization parameter. When 𝜆 𝑇𝑉 < 10−6 , RL-TV deconvolution is dominated
by the data model; when 𝜆 𝑇𝑉 approaches 1, RL-TV deconvolution is dominated by the
regularization term.
IV.

Anatomy image-guided image restoration

In this method proposed by Wang and Fei (200), PVC is considered as a least square minimization
to restore the true radioactivity 𝑜(𝑟) from an observed PET 𝑖(𝑟) and a known PSF ℎ(𝑟):
2

𝐽𝑑𝑒𝑐𝑜𝑛𝑣𝑜𝑙𝑢𝑡𝑖𝑜𝑛 = ∑𝑟(𝑖(𝑟) − 𝑜(𝑟)⨂ℎ(𝑟)) .
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(25)

It also leads to noise amplification and severe ring artifacts, therefore prior knowledge about 𝑜(𝑟)
is required to regularize the minimization. Then 𝑜(𝑟) is restored by minimizing of the cost function
consisting of the term describing the sum of squared difference (data fidelity term) and a second
term expressing the edge constraint:
𝑤

𝑜 = 𝑎𝑟𝑔 min 𝐽(𝑜) = 𝑎𝑟𝑔 min[∑𝑟(𝑖(𝑟) − 𝑜(𝑟) ⊗ ℎ(𝑟))2 + 𝜆 ∑𝑟 ∑𝑘∈𝑁(𝑟) 𝑑 𝑟𝑘 (𝑜(𝑟) − 𝑜(𝑘))2 ].
𝑜

𝑜

𝑟𝑘

(26)
The minimization is here calculated by the conjugate gradient (CG) method. The CG scheme
guarantees descent. The CG minimization requires analytical derivatives of the cost function with
respect to the true radioactivity in each pixel, which is given as:
∂𝐽
∂𝑜(𝑟)

𝑤

= 2 (( 𝑜(𝑟) ⊗ ℎ(𝑟) − 𝑖(𝑟)) ∗ ℎ(𝑟) + 4𝜆 ∑𝑘∈𝑁(𝑟) 𝑑 𝑟𝑘 (𝑜(𝑟) − 𝑜(𝑘))),

(27)

𝑟𝑘

, where ∗ denotes the correlation operator (because the PSF h is a symmetric Gaussian function,
the correlation is equivalent to a convolution operation here), ⊗ denotes the convolution operator,
𝜆 denotes the balance parameter, 𝑤𝑟𝑘 is the weighting coefficient that determines the weight to
enforce the regularization:
△ork 2

wrk = exp (− (

μ

1
0
1
{0

△ork 2

) ) + [1 − ex p( − (

μ

△ork 2

) ). , ] exp (− (

ν

|△ ork | ≪ μ
|△ ork | ≫ ν
μ < |△ ork | < ν and |△ lrk | ≪ κ
μ < |△ ork | < ν and |△ lrk | ≫ κ
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△lrk 2

) ) exp (− (

κ

) )≈

(28)

, where △ ork = or − ok and △ lrk = MRIr −MRIk , μ and ν are the radioactivity thresholds with
μ < ν, κ is threshold to determine an edge present in MRI, by which an edge is considered to
appear if the intensity difference between the neighboring voxels is greater than κ. If |△ ork | is
smaller than μ which indicates substantial smoothness between voxel r and k at PET, wrk ≈ 1, and
the constraint for PET activity continuity is switched on. In contrast, when |△ ork |is greater than
ν which denotes there is there is an edge between r and k, wrk ≈ 0 to switch off the intensity
constraint. For neighboring voxels which have radioactivity difference between μ and ν, MRI edge
information is employed to ensure that there is an edge in the corrected image by wrk ≈ 0 if MRI
presents an edge with |△ lrk | ≫ κ.
The CG minimization is performed by iterate update of the conjugate direction and the solution is
denoted as:
𝑜𝑚+1 = 𝑜𝑚 +∝ 𝑑𝑚 ,

(29)

where m is the iteration number, 𝑑 𝑚 is the conjugate direction, and ∝ is a positive step size which
is determined by a line search (200).

4.1.3.2 Evaluation of PVC methods using simulated PET images
I.

Materials and methods

The 4 PVC methods were first validated using a synthetic dataset generated in MATLAB. The
synthetic dataset started with a given true “radiotracer” distribution on a 64×64×64 image which
consisted of three rows of spheres, each row had 3 horizontal spheres, with different sizes (3.0,
1.0, 2.0 times of PSF FWHM (4 pixels) in diameter) and “radioactivity” intensities (20, 40, 60) in
a large background sphere with intensity of 5 resulting in different contrasts of the spheres with
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respect to the background. This true radioactivity image was added with Gaussian white noise of
different levels (1%, 5%, 8%, and 12%) relative to the background activity. Then the noisy PET
images were convoluted with a 3D Gaussian function having FWHMs of 4 pixels. The convolution
simulated the PSF blurring of the true radioactivity signal. The PSF and image size were given
with a unit of pixel which can be easily mapped to typical MRI and PET resolutions.
The anatomical images for the GTM method and anatomy image-guided method was created as a
digital mask in MATLAB in the same dimension and voxel size as the simulated PET images. The
intensities of the spheres, background, and outside background were semi-arbitrary – they can be
any combination of values as long as the MRI edge constraint parameter κ used in the anatomyimage guided PVC algorithm is between the intensities of the spheres and the background. We set
them 20, 5 and 0, respective, and therefore chose 10 as the value of κ.
II.

Results

All 4 PVC methods improved the shape and intensities of the spheres in the simulated PET images
and the results are presented in (Fig. 45). The GTM method was the simplest to implement and
fastest to execute. The requirement of well-segmented ROIs with homogeneous tracer intensities
was also easy to achieve in this digital phantom because all prior anatomical information was
known. RL deconvolution was also an easy and fast PVC method, but it tended to amplify noise
and generated Gibb’s ring artifacts with increasing number of iterations. These unwanted side
effects were successfully removed in RL-TV method during iterative deconvolution at the expense
of extra running time. The calculation time of RL-TV method for an image with matrix size of
64×64×64 is about 3 minutes, while it take less than 10 seconds to complete the calculation using
the RL method on the same image. The anatomy image-guided image restoration method
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iteratively de-convolved the PET images with PET and MR based edge-preserving constrains. It
is the slowest and most complicated PVC method among the four, but most accurately recovered
the activity in objects of all size studied.

Figure 45 Partial volume correction of a simulated 64×64×64 3D image. (A) The sagittal view of center slice of the
synthesized 3D digital phantom with true tracer radioactivity distribution. From left to right, the rows are objects
having diameters of 1, 3, 2 times of PSF-FWHM. From top to bottom, the column are objects having tracer intensities
of 20, 40 and 60. The background is a larger sphere with 60 pixels in diameter and tracer intensity is 50. (B) A
representative simulated PET image created by convolving PSF with image from (A) with 12% Gaussian noise. Center
slice of (B) the resultant partial volume corrected PET image using (C) anatomy image-guided method with λ = 0.005,
μ = 0.5, ν = 10, κ = 4, (D) RL method, (E) RL-TV method with λTV = 0.01, which is chosen based on trials to achieve
highest recovery coefficients but eliminate Gibbs ringing artifacts, and (F) geometric transfer matrix (GTM) method.

Table 5 compares the recovery coefficients of the spheres and the noise level in PET images using
the 4 PVC methods. The recovery coefficients were less affected by the contrast and the added
Gaussian noise in this digital phantom, probably because their contrasts relative to the background
were all relatively high and the Gaussian noise levels were all relatively low. Generally, the larger
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the size of an object, the less it would be affected by PVEs, and the PVC methods worked better
to recover its tracer intensity. In this simulated phantom, the anatomy image-guided method was
able to recover near 100% of the average radioactivity in each spheres. RL-TV did not result in
better recovery coefficients compared the RL method and it’s affected its regularization parameter
which will be discussed in the next section. The recovery coefficients of the spheres were lifted
with respect to increasing regularization parameter (λ) using the anatomy image-guided method,
but lowered using the RL-TV method. For both anatomy image-guided and RL-TV methods, the
noise in the recovered images were reduced with respect to more weighting of the regularization
terms (larger λ), therefore it’s important to choose an optimized regularization parameter to
balance the recovery coefficients and image noise level.
Table 5 Summary of recovery coefficients of the spheres and noise levels in the unrecovered simulated
PET image (12% GWN) and corrected PET images using the 4 PVC methods.



Although the RL-TV method was faster than the anatomy image-guided method for the
computation to reach a convergence, it did require a higher number of iterations which might
generate more noise. Despite the difference in minimum values of the cost functions for the PET
images of difference noise levels, the rates of convergence were always the same when the same
PVC method and same parameters were chosen. (Fig. 46).
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Figure 46 Comparison of rates of convergence using (A) anatomy image-guided method (λ = 0.005, μ = 0.5, ν = 10,
κ = 4), and (B) RL and RL-TV (λTV = 0.01) method with different levels of Gaussian white noise.

4.1.3.3 Evaluation of PVC methods using an atherosclerotic plaque phantoms
I.

Materials and methods

The 4 PVC methods were then evaluated on hand-made phantoms that simulated irregularly
shaped plaque deposits of various thickness and activity concentrations on a blood vessel wall. For
this phantom, 52Mn was mixed with epoxy and a thin layer was deposited on the inner wall of 5
ml vials. The long half-life of 52Mn (5.6 days) enabled long periods of study. The maximum and
mean β+ energy, and maximum and mean positron range of

52

Mn (0.575 MeV, 0.245 MeV, 2.5

mm, and 0.63 mm, respectively) (218) are comparable to that of 64Cu (0.653 MeV, 0.278 MeV,
2.9 mm, and 0.56 mm, respectively) (219), rendering its capacity to be used as a substitute to study
the spatial resolution of 64Cu-ATSM PET images. The property of epoxy material made it easy to
create 52Mn-glue deposit with comparable structure and shape to mimick human carotid plaques.
The 5ml vial had a similar diameter (16 mm) to larger human arteries. Six plaque phantoms were
created: three phantoms with 2.0 µCi

52

Mn in ~25µl epoxy, one with 9.6 µCi

52

Mn in ~100 µl

epoxy, one with 22.0 µCi 52Mn in ~200 µl epoxy, and one with 27.2 µCi 52Mn in ~300 µl epoxy
(Fig. 47). The true activity in the phantom was measured in a dose calibrator.
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The phantom was imaged in the Siemens F220 microPET small animal PET scanner and
reconstructed by the 2D-OSEM algorithm, using 16 subsets and 4 iterations with scattering and
attenuation corrections, into a 128×128×159 matrix with 0.78×0.78×0.80 mm voxel size.
The small animal PET scanner had an approximately 1.8 mm spatial resolution (220) and therefore
1.8 mm was used as the PSF FWHM for the PVC methods. High-resolution CT imaging were
acquired and used to delineate the lesions and determined their exact shape and dimensions. The
reconstructed CT images had a matrix dimension of 512×512×512 and a voxel size of 0.2×0.2×0.2
mm. The reconstructed PET and CT images were registered and analyzed on Inveon Research
Workplace (IRW; Siemens Medical Solutions USA, Inc., Malvern, PA).
II.

The anatomy images for the GTM method and anatomy image-guided method were
created as a digital mask in MATLAB based on the CT images, but interpolated and
cropped to the same dimension and voxel size as the PET images. Only the “plaques”
themselves that had radioactivity were included in the digital mask with an intensity of
10, and the background intensity was set to 0. These values, as the intensities of the
anatomy image in the simulated digital phantom, are semi-arbitrary. They can be any
combination of values as long as the MRI edge constraint parameter κ used in the
anatomy-image guided PVC method is between the intensities of the “plaques” and the
background. Results

The 2D-OSEM reconstructed PET images (Fig. 48) blurred by PVEs could be corrected by any
one the 4 PVC methods (Fig. 49). It revealed similar advantages and disadvantages of using these
PVC methods on real PET images compared to the simulated PET images as discussed in the
previous section.
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Figure 47 Set-up of plaque phantoms. (A) Sagittal and (B) transverse view of an individual plaque phantom of epoxy
not mixed with 52Mn. (C) Sagittal view of a plaque phantom mixed with 52Mn. (D) Loctite® expoxy gel before the
use. (E) 6 plaque phantoms were bundled with tape and placed in a lead shield in preparation for PET/CT scanning.
(F) The bundled plaque phantoms were placed on the animal bed of the animal PET/CT scanner.

Figure 48 Coronal (top) and sagittal view of different slice of the fused PET/CT images showing the location and
radioactivity intensities of 6 plaque phantoms.
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Figure 49 Application of PVC methods to the PET images of plaque phantoms. Transverse view of a selected slice
of (A) simulated digital mask of true radioactivity concentration, (B) uncorrected PET image, and PET image
corrected by (C) GTM method, (D) RL method, (E) RL-TV method with λTV = 0.01, and (F) anatomy image-guided
method with λ = 0.005, μ = 10, ν = 800, κ = 5.

Table 6 summarized the total radioactivity of each carotid plaque phantom (ROI) in the
uncorrected and corrected PET images, and the percentage difference from the measured
radioactivity over the true activity, using the 4 PVC methods with representative regularization
parameters (in applicable). The average radioactivity was calculated by multiplying the average
radioactivity in the ROI measured in PET images by the total volume of the ROI measured in HD
CT images after a segmentation process. PVEs resulted in an underestimation of the radioactivity
of as much as greater than 20% (Table 6). All PVC methods were able to reduce the errors in
radioactivity measurements to less than 10%. If was difficult to fully recover all plaque phantoms
due to their different intensities and sizes, however full recovery of certain plaques for specific
purpose was achievable by adjusting the parameters in the RL-TV and image-guided method. For
example, as shown in Table 6, given λ = 0.01 and λ = 0.005 for the RL-TV and image-guided
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methods respectively, ROI1, ROI2, ROI3, and ROI6 could achieve less 5% differences between
the true and partial volume corrected activities.
Table 6 Total activity of each ROI in the uncorrected and corrected PET images, and the percentage
difference from the measured activity over the true activity.

The recovered radioactivity and recovery coefficients using the RL-TV and anatomy-image guided
PVC methods were affected by the regularization parameter λ (Fig. 50, Fig. 51). Regularization
parameters also changed the stop point of the converge using the RL-TV and anatomy-image
guided methods, but the iteration number to achieve convergence was not affected if other
parameters were kept constant (Fig. 52).
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Figure 50 Comparison of true radioactivity concentrations of the 6 plaque phantoms (ROIs) to the measured mean
radioactivity concentrations in the uncorrected PET image and PET image corrected by the 4 PVC methods with
different regularization parameters as shown in the parenthesis of the legends. The μ, ν and κ used in the anatomy
image-guided method were 10, 800, and 5, respectively.
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Figure 51 Comparison of recovery coefficients of the 6 plaque phantoms (ROIs) in the uncorrected PET image and
PET image corrected by the 4 PVC methods with different regularization parameters as shown in the parenthesis of
the legends. The μ, ν and κ used in the anatomy image-guided method were 10, 800, and 5, respectively. The recovery
coefficients of the digital mask with true activity concentrations is 1.0.

Figure 52 Comparison of rates of convergence using (A) anatomy image-guided method and (B) RL and RL-TV
iterative deconvolution methods on the PET image of plaque phantoms using different regularization parameters as
shown in the parenthesis of the legends. The μ, ν and κ used in the anatomy image-guided method were 10, 800, and
5, respectively.

4.1.3.4 Evaluation of PVC methods using clinical 64Cu-ATSM PET/MR images of
atherosclerotic plaques
I.

Materials and methods

The 30-60 min carotid 64Cu-ATSM PET image was reconstructed using the PSF–OSEM algorithm
with 24 subsets, 8 iterations, and a 2-mm FWHM Gaussian post reconstruction smoothing filter.
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A voxel size of 1.04×1.04×2.03 mm and matrix size of 344×344×127 was used. We evaluated the
MR-guided, RL, and RL-TV, and GTM methods for partial volume correction. The PET images
had approximately 4.2 mm effective spatial resolution based on previous measurement using the
spherical phantom and using the same reconstruction parameters in PSF-OSEM algorithm (Fig.
40), therefore this 4.2 mm was used as the PSF FWHM for the PVC methods.
I.

Results

All the evaluated PVC methods worked to improved signal intensity measurement of the plaque
but not the background tissues (Fig. 53, Fig. 54, and Fig. 55(A)). The T1-weighted MR image used
for the anatomy image-guided method was processed beforehand by thresholding segmentation to
improve contrast between the plaque and surround tissues, therefore a sharp edge was shown
around the plaque in the corrected PET images. Ideally, the MR sequence would provide the
appropriate contrast to allow for easy identification of the structure which would coincide to the
areas of uptake by the PET tracer, then this algorithm will use an edge seen in MR and enhance an
edge seen in PET. However, in reality the MR image of carotid plaques is not able to provide good
enough contrast without pre-processing.
Similarly, because accurate segmentation of plaques into ROIs with homogenous radioactivity is
difficult, GTM method can only provide a regional radioactivity in the ROI, but not corrected PET
image on the voxel level (Fig. 54).
Due to PVC, the plaque-to-background signal intensity ratio which corresponded their
radioactivity concentration ratio improved from 2 in the uncorrected PET image to 2.5-3.5 in the
corrected PET images. The gain in RC varied depended on the different combinations of
deconvolution parameters (Fig. 55(B)). Anatomy image (MRI)-guided method generally
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generated higher ratios; RL-TV method does not improve the ratio compared to RL method,
although it might work to remove the noise generated in RL deconvolution.
The results suggested that these PVC methods could potentially assist physicians to diagnose
plaques using

64

Cu-ATSM PET/MR imaging. In

64

Cu-ATSM PET images, we measure the

average activity concentration in the plaque and used the plaque-to-background SUV ratios to
differentiate subjects with and without hypoxic vulnerable plaques. The improved plaque-tobackground contrast ratios in the partial volume corrected PET images therefore will make the
plaques easier and more precise to be identified. One the other hand, PVC restores the PET images
that may improve the accuracy of quantitative estimation of the true activity of the plaques.
Assuming that the uptake of 64Cu-ATSM is associated with plaque hypoxic level, and thereby the
vulnerability of the plaque, knowing the true activity will be valuable to determine the likelihood
that the patient’s plaque will rupture. However, further validation with more data and IHC staining
are necessary to get these PVC methods clinically applicable. With the correlation of 64Cu-ATSM
spatial distribution as well as activity concentrations in partial volume effect corrected PET images
to IHC staining of PIMO, HIF and macrophages, we will be able to demonstrate the hypothesis
that PVC improves the qualitative estimation and quantitative measurement of hypoxic plaques
using 64Cu-ATSM PET images. Unfortunately, for reasons out of our control, we did not get IHC
data to compare with yet, but the work will continue.

115

Figure 53 Application of PVC methods in clinical 64Cu-ATSM PET/MR images of atherosclerotic plaques on the
vertebral artery (patient #5). Transverse view of (A) 64Cu-ATSM PET image fused with T1-weighted MR image and
(D) T1-weighted MR image. (B) Region of interest indicating the vertebral plaque and surrounding tissue in blue box.
Representative PVC corrected images using (C) anatomy image (MRI)-guided method with λ = 0.001, μ = 0.5, ν =
200, κ = 100, (E) RL method, and (F) RL-TV method with λTV = 0.01.

Figure 54 Application of GTM PVC method in clinical 64Cu-ATSM PET/MR images of atherosclerotic plaques on
the vertebral artery (patient #5). Transverse view of (A) 64Cu-ATSM PET image fused with T 1-weighted MR image
was zoomed in with the region of interests on the vertebral plaque and surrounding tissue in blue box. (B-D) shows
the uncorrected PET image, PET imaged segmented into homogeneous ROIs and PET image after GTM partial
volume correction.
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Figure 55 Comparison of the PVC results of 64Cu-ATSM PET images of atherosclerotic plaques. (A) Mean
radioactivity concentrations measured in the plaques and background of the uncorrected PET image, and image
corrected by RL, RL-TV, and MR-guided PVC methods with various parameters as shown in the parenthesis of the
legends. The μ, ν and κ used in the MR-guided method were 0.5, 200 and 100, respectively. (B) The corresponding
plaque-to-background intensity (radioactivity concentration) ratio of the uncorrected PET image and the corrected
PET images.

4.1.3.4 PVC via post-reconstruction image processing: discussion
We compared the effectiveness of various PVC methods with simulated data and homemade
carotid phantoms and demonstrated that PVC was an effective image processing approach to
improve the PET image quality in terms of its contrast, and may be a promising approach to
improve the qualitative detection and/or quantitative measurement of hypoxic plaques at different
levels of accuracy in carotid 64Cu-ATSM PET/MR imaging, though further studies to correlate the
partial volume recovered radiotracer activity and PET image to immunohistochemistry staining
are necessary to validate the efficiency the PVC methods.
The ultimate goal of PVC is to reverse the effect of the system PSF in PET images and thereby
qualitatively and quantitatively restore the true activity distribution. This can be achieved regionor ROI-based post-reconstruction approach that attempts to recover true radioactivity in the region
level with the assumption of homogeneous radioactivity distribution with each ROI. Usually these
ROIs are obtained by segmenting or classifying the co-registered anatomical images into a number
of non-overlapping compartments (221). GTM method is a typical ROI-based method where a
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regional point spread function is computed for each ROI by PSF convolution of the region
assuming unit radioactivity (186), and then linear equations are formed to solve the regional
corrections. The GTM approach not only requires registration and segmentation of anatomical
images but also need the knowledge about regional structural and functional correspondence to
satisfy the assumption of regionally homogeneous radioactivity. This is apparent in the initial
proposed application of this approach – brain, which can be easily segmented into large ROIs of
gray matter, white matter, and cerebrospinal fluid (CSF) in MR images (186). However, the
segmentation of carotid plaque, on the scale of millimeter level, is more difficult. The
homogeneous radioactivity assumption implies that the correction is performed between voxels in
different segmented regions, but not between voxels in the same region (191). Considering the
complex composition of atherosclerotic plaques, PVC should thus be considered, not as an exact
correction, but as a first order approximation.
PVC can be also done by voxel-based deconvolution, either in the image domain post
reconstruction or during iterative image reconstruction by incorporating the PSF in the system
matrix such as the PSF-OSEM algorithm. The deconvolution during image reconstruction has a
superior noise performance because a larger number of measured data values are involved in the
reconstruction of each voxel value, resulting in noise averaging (191). However, similarly to the
post-reconstruction deconvolution, the resulting images often suffer from so called ‘Gibbs ringing
artifacts’, corresponding to ringing in the vicinity of sharp boundaries, which is related to missing
high frequency information in the measurement. This could be caused by insufficient sampling in
the image domain by the use of too large voxels. The RL iterative algorithm is post-reconstruction
deconvolution PVC method derived for Poisson noise (215, 216) and commonly used in astronomy
and microscopy image enhancement (217, 222). RL assumes that the Poisson noise model is
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adequate for PET. The number of detected photons is a Poisson process whose variance is equal
of the mean of the number of counted photons. The main advantage of the RL deconvolution PVC
method is that it depends on PET image data only, and no anatomical data is needed. However the
inclusion of anatomical information allows to increase PET signal contrast and improves
quantitation accuracy at the lesion boundaries if properly identified. The main undesired property
of the RL algorithm is that, in the presence of noise, deconvolution process converges to a solution
which is dominated by noise (223). Because of the ill-conditioned nature of the deconvolutionbased restoration problem, some sort of regularization must be used to avoid high-frequency noiseamplification and introduction of artifacts. This can be achieved in a variety of ways such as early
iteration termination, post-reconstruction filter or by incorporating a regularization term or
anatomical information and tissue homogeneity constraints into the deconvolution iteration. The
total variation (TV) regularization is often applied in the RL algorithm (217, 222) to increase the
sharpness of object borders and obtain smooth homogeneous areas (223). It assumes uniform
uptake within regions. This algorithm and many similar approached introduce a balancing
parameter that allows to weigh in the importance of the penalty term with respect to the data
fidelity term. In RL-TV, this parameter is TV. We determined the regularization parameters by
optimization of the recovery coefficients. Some studies estimate the TV regularization parameter
from the images as the algorithm process (222). The anatomical image-guided PVC methods, in
contrast utilizes structural information from other imaging modalities as a priori information (in
the form of a penalty terms) in order to favor solutions where lesion edges in the anatomical images
are used to emphasize contrast in the PET images. We make the assumption that the identified
structure in the anatomical image is the region of increase uptake in PET, which is not necessarily
true for other cases. Regularization term (the weighting coefficient) in this method contains 4
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unknown parameters that must be carefully chosen to achieve optimal deconvolution results that
would be as close as possible to the ‘true’ image.
To accurately measure uptake in small structures is challenging, and PVC is even more challenging
in preclinical imaging of rodents where structures are extremely small relative to the achievable
resolution even on preclinical small-animal scanner (~1.8 mm for Siemens microPET/CT scanner).
In addition, for PVC in small animal preclinical imaging it may be important to take into account
the spatial variation of the PSF as well as the positron range in the case of PET (191). However,
since our dedicated animal (mouse and rabbit) models were developed for demonstrating the
ability of 64Cu-ATSM to image hypoxic plaques, there was no quantitative end point where the
absolute level of tracer uptake was required.
It should also be pointed out that image noise and noise correlations, as well as the precision of
quantitative estimates of activity, are measures that can often be equally important as image fidelity
or quantitative accuracy (191), and therefore it is crucial to evaluate on the noise handling of the
PVC methods in further studies. Also the sensitivity of PVC techniques to error in pre-correction
processing steps, such as registration and segmentation in anatomically guided methods should be
evaluated.
To conclude this section, PVC is an important aspect of quantitative analysis in PET and remains
an area of active research. A large number of different methods for PVC have been proposed in
the past – some methods utilize anatomical information while some do not. Some methods produce
only mean values for one or more regions, while some perform a voxel-by-voxel correction for a
region or the whole image. Some methods are applied to a reconstructed image, while some are
incorporated in the reconstruction algorithm. Although these PVC methods were originally
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developed for cardiology, neurology or oncology with either PET or SPECT, most methods may
be applicable in multiple areas.

However, although their application is theoretically

straightforward for the most part, it is difficult in practice. A given, very specific problem may
require extensive validation and this was the purpose of our study. The validation also need to be
done against a gold standard. In this case, it would have been IHC staining which would have
provided the absolute hypoxic level value. Unfortunately, we don’t have IHC data yet.
Conventionally, it is believed that there is no need for clinical evaluation of PVC methods and
PVCs are believed to increase variance. Nevertheless, as the systems of multimodality systems,
which combine PET (or SPECT) with CT or MRI to allow acquisition of co-registered functional
and anatomical images, are becoming widely available, we can expect that the time has come for
PVC to be routinely used in clinical practice including but not limited to carotid plaque

64

Cu-

ATSM PET/MR imaging.

4.2 Correction for attenuation effects due to the carotid
surface coil and the thermoplastic holder
PET is a fully quantitative technology and well known to be affection from attenuation of the
annihilation photons in the body by photo-electric effect and by Compton scatter, one reason being
that true coincidence events are absorbed in the body. Attenuation correction (AC) for photon
attenuation is thus an essential step when reconstructing high-quality, quantitatively accurate PET
images. In PET-CT, attenuation correction is performed routinely based on the available CT
transmission data (224). In PET-MR, most MR-AC strategies require the use of complementary
MR or morphology templates generated from MR images. MR-AC consists of MR image
acquisition, segmentation, truncation compensation, µ-value assignment, and correction for patient
table and RF coils. (225)
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Yet one challenge to the MR-AC approach is the absence of the flexible body or surface coils in
the MR attenuation correction. Although built using low density material and judicious placement
of the electronic components, these coil will show some attenuation to annihilation photons. Radiofrequency (RF) receiver coils are commonly placed as close to the subject as possible to maximize
SNR in MR data acquisition. It has been recognized that these coils will attenuate (and scatter)
annihilation photon emission data if they are present inside and during the PET scan. These coils
do not appear in the MR image (226). As such, an AC map (μ-map) derived purely from an MRI
will not be complete because it lacks the coil structure that also causes attenuation. Static coils
(head/neck, spine) and patient bed can be integrated into the μ-map via templates (227, 228).
However, the carotid surface coils as well as the thermoplastic holder that was used to fixed the
patient’s neck to minimize motion artifacts used in our study contain elastic components and hence
cannot be located easily with respect to the gradient coil or the patient.
This situation is much more difficult to treat with a template AC method because the active
components of the coil can be in different position relative to each other, meaning a previously
acquired scan may not match the distribution of attenuating material in a patient scan. Despite the
optimization of surface coils for PET (design, low-attenuating materials), it may still introduce
errors in MR-AC (224, 225, 229, 230). Neglecting the attenuation effects caused by MR body
surface coils in combined PET/MR imaging leads to as much as 20% underestimation bias in
measured activity concentration (231).
Currently, in our Siemens mMR whole-body PET/MR system, a MR attenuation μ-map is derived
from a 2-point Dixon VIBE (volumetric interpolated breath-hold examination) sequence that
generates a water only, fat only, in-phase, and opposed phase imaging series (232). Dixon-based
MR-AC is a tissue segmentation approach that permits segmentation of fat, soft tissue, lung and
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air (233). The attenuation effects resulting from the carotid surface coil will be taken in
consideration in the Dixon-based MR attenuation μ-map.
Some methods of estimating the amount of attenuation caused by MRI surface coils in the PET
field of view during combined PET/MRI scanning have been reported to achieve accurate
quantitative recovery in the PET images (231, 234, 235). We applied a method that was modified
from a recently published template approach developed by our colleagues in Washington
University (227, 228, 236), in which the coils and holder were imaged beforehand in a CT scanner,
then converted into appropriate attenuation correction μ-maps for PET data, and inserted into the
AC map for the object being imaged.

4.2.1 Correction for attenuation effects: material and methods
I. Validation with Phantom: Set-up
The phantom was created using a 2-liter (~10 cm in diameter) cylindrical plastic bottle that
was completed filled with distilled water. The bottle was wrapped with the 2 pieces of carotid
surface coils on sides and secured on a block of Styrofoam with the thermoplastic holder and paper
tape. The 3T carotid surface coil used at our institution is a dedicated two sided, four-channel
phased array surface coil (Machnet, Netherlands) to improve the signal-to-noise ratio in carotid
arteries. The effective length of the coil in the anterior posterior direction is 105 mm, and the width
is 60 mm. The carotid coils were rigidly attached to the thermoplastic holder. 4 Vitamin E capsules
were place on each piece carotid coil, secured with paper tape, as the fiducial markers for
visualization in PET/MR imaging (Fig. 56).
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Figure 56 Pictures showing the set-up of radioactive phantom and the places to place the fiducial markers on the
carotid coils.

II.

High-Resolution CT

A CT scout scan was acquired on a Biograph 40 TruePoint PET/CT (Siemens Healthcare) followed
by a high-resolution, low-amperage CT scan with the following parameters: 120-kV collimation,
1.5-mm slice thickness (40×0.6 mm), 35 mAs, and 300-cm FOV. Images were reconstructed with
1.5-mm slice thickness and 0.48-mm pixel size on a 512×512 matrix. This scan provided the
template images that were registered to the anatomic MR attenuation map.
III.

Transmission scan

A 45-min transmission scan of the phantom was obtained on a Focus 220 small-animal PET
scanner (Siemens Medical Solutions) using a rotating
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Co point source. The
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Co transmission

image (attenuation map) was reconstructed using the maximum a posteriori (MAP) reconstruction
algorithm and analyzed with ASIPro (Siemens Medical Solutions) to measure the attenuation
coefficient of the coil. The known attenuation coefficient of water for 511 keV photon provided the
reference.
IV.

Image Processing
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The CT images of the phantom were processed in MATLAB to create a digital mask that extracted
the pixels elements only belonging to the carotid coils and thermoplastic holder. The measured CT
Hounsfield unites of the carotid coils and thermoplastic holder were then scaled to the attenuation
coefficients, by the equation:
𝐻𝑈 = 1000 × 𝜇

𝜇−𝜇𝑤𝑎𝑡𝑒𝑟
𝑤𝑎𝑡𝑒𝑟 −𝜇𝑎𝑖𝑟

,

(30)

where μ is the average linear attenuation coefficient in a voxel of carotid coils or thermoplastic
holder, 𝜇𝑤𝑎𝑡𝑒𝑟 and 𝜇𝑎𝑖𝑟 are respectively the attenuation coefficient of water and air. The digital
mask was split into its left and right halves. The fiducial markers were identified in the CT images
and co-localized the water-only images acquired in the MR-AC acquisition. Rigid point based
registration was performed to align the fiducial markers in the images of the RF-coil/holder CT
images to the fiducial markers on the MR images for each half of RF-coil/holder arrangement. The
algorithm proceeded by the least square minimization of the three dimensional distances in CT
and MR images through successive operation of rotations and translations. Minimization was
performed using Powell minimization algorithm in IDL. Each half of the CT template was then
overlaid on the measured MR-AC u-maps of the phantom. Clinical human carotid plaque 64CuATSM PET/MR images then were used to evaluate the carotid coil attenuation correction method.
The fiducial makers (Vitamin E pills) were used to locate the carotid coils (and thermoplastic
holder). The spatial location of the fiducial markers, with respect to the MR scanner coordinates,
were clearly visualized with the 2-point Dixon MR imaging sequence and extracted from the
water-only MR images using this sequence. A 3D rigid transformation of CT template of the
carotid coil was then performed to minimize the sum of the square difference of the spatial location
of the fiducial markers as seen on the CT template and in-phase MR images. The algorithm was
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coded in IDL, version 8.1 (Interactive Data Language, Exelis Inc.), and used the Powell
minimization algorithm (236).
In order to validate the accuracy of the correction, we used the same bottle phantom filled with 37
MBq (1 mCi) 18F-FDG and water, compared the measurements of decay-corrected radioactivity
concentration in PET/MR images with carotid coils on and off.

4.2.2 Correction for attenuation effects: results
A digital mask of CT template in Hounsfield unites (HU) of the carotid coils and thermoplastic
holder was created from the CT template. The water ROI on the Focus 220
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image revealed a measured attenuation coefficient of 0.092 cm-1 which was consistent to the
nominal value (0.092 cm-1), indicating an accurate calibration of the Focus 220 for attenuation
correction measurement. The measured CT Hounsfield unites of the carotid coils and thermoplastic
holder (approximately on the range 500-3000) scaled to the attenuation coefficients were mostly
on the range 0.1-0.3 cm-1. The digital mask was interpolated to have a matrix size of 344×344×127
with a voxel size of 2.08626×2.08626×2.03125 mm3 in order to in order to match the dimension
of the MR attenuation map (Fig. 57).
The overall improvement in radioactivity concentration of 64Cu-ATSM PET images with carotid
coil attenuation correction was on average 7.6% (Fig. 58). The coil attenuation effects were not
equally distributed in PET images; higher effects were found around the neck of the patient where
the coils were placed (Fig. 59).
The results of the bottle phantom with and without coil in 18F-FDG PET/MR imaging showed that
the average attenuation effects due to carotid coils was 6.2% (Fig. 60). This number was a little
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smaller but reasonable compared to the improvements with attenuation effects correction in our
study, considering that we also took the effects from thermoplastic holder into account.

Figure 57 From left to right, the coronal view of the CT template of carotid coils and thermoplastic holder in CT
Hounsfield unites, the uncorrected MR attenuation μ-map acquired by the 2-point Dixon MR imaging sequence, and
the μ-map that incorporated the carotid coils and thermoplastic holder.

Figure 58 Coronal and sagittal views of 64Cu-ATSM PET images without and with carotid coil attenuation effects
correction. The activity concentration (nCi/cc) was measured on the top, middle, bottom and overall regions of the
patient’s neck, and the relative improvements with carotid coil attenuation effects correction were calculated
respectively (right panel).
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Figure 59 From left to right, coronal and sagittal views of 64Cu-ATSM PET images focused on the neck area of the
patient without and with carotid coil attenuation effects correction and the relative improvement in activity
concentration on each pixel after correction.

Figure 60 From top to bottom, 18F-FDG PET images of bottle phantom with and without carotid coils. From left to
right, transverse, sagittal and coronal views of the PET images. The attenuation effect from the carotid coils is overall
6.2% and equally distributed in the phantom.
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4.2.3 Correction for attenuation effects: discussion
We used a template approach to incorporate the attenuation effects of the carotid surface coils and
neck thermoplastic holder into the MR attenuation µ-map for carotid artery

64

Cu-ATSM PET

image reconstruction.
Due to the inhomogeneous improve in radioactivity concentration in the PET images, the
attenuation correction method can be potentially used in human carotid plaque

64

Cu-ATSM

PET/MR images to improve the accuracy of measured target-to-background ratios.
In addition to the template approach, ultrashort echo time (UTE) MR sequences, as well as the
combine UTE-Dixon sequence, shows promise to correct for attenuation effects from carotid coils.
The UTE uses a greatly reduced echo time to capture rapidly decaying signals have demonstrated
the ability to detect a signal from even cortical bone (237). Hofmann et al claimed that MR
sequences with UTE could possibly help detect surface coil landmarks and thus account for their
attenuation (224). Eldib et al used a combination of and non-rigid registration of a CT-based
attenuation map and the UTE image of carotid coils for markless attenuation correction (238).
However, UTE-based sequences are not yet FDA approved for clinical use (236)
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Chapter 5: Commercialization of
64
Cu-ATSM
At the end my doctoral training, I completed a 3-month internship/co-op as a data analyst in a
healthcare consulting company named Velocity Biogroup, Inc. in Philadelphia, PA.
During this co-op, I started with learning the United States laws and policies regarding patent and
intellectual property, FDA approval regularizations, the respective coverage of Medicaid and
Medicare programs, and so on. Since it was a biomedical product oriented company, I was
significantly involved in reviewing and evaluating the new medical devices and brand name drugs
or FDA 505(b)(2) approved generic drugs for the company’s clients from the US and other
countries (e.g. France, Korea, India) who are seeking for their markets in the US. I also helped to
develop a recipe to extract useful information from a big healthcare database using MySQL and
IBM Watson Analytics service, and visualize the results with the company-owned software.
In the meanwhile, I put some of my focus to think of how to move the imaging agent 64Cu-ATSM
from the preclinical studies into patients in light of what I’ve learned during the co-op in terms of
translation and innovation.

64

Cu-ATSM is currently an FDA approved investigational new drug

(IND), but it was first synthesized 20 years and a lot of groups worldwide are able to make 64CuATSM compounds. Despite that we disclosed the potential usage of

64

Cu-ATSM in imaging

hypoxic carotid atherosclerosis in PET, it is not patent protected. In order to get 64Cu-ATSM FDA
approved for this specific aim, a large-scale Phase II and/or Phase III clinical trial is necessary.
This, however, takes a lot of time, money and efforts. It might be doubtfully to devote such great
resources to perform the clinical trial for very limited commercial opportunities, even though there
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is no obstacle to recruit patients in the strict condition of vulnerable carotid plaques who may have
to undertake carotid endarterectomy.
However, given that this agent is disclosed, there are still some commercial opportunities open to
us as a university which can manufacture it, because we are one of the only 3-4 facilities in the
United States who makes 64Cu weekly by an on-site cryotron. We have rich connections and plenty
of experience to supply
supplier of

64

64

Cu to other facilities, and therefore we can be the most convenient

Cu-ATSM to those facilities who can’t either make

64

Cu or ATSM themselves.

Without a large-scale clinical trial, 64Cu-ATSM alone may not be used as the direct predictor of
carotid vulnerable plaques, but as a supportive evidence of it. The 64Cu-ATSM uptake in the PET
and plaque MR image of the patient will then be recorded and saved in the patient’s database,
together with other information of the patient, such as his/her age, gender, weight, ethnicity,
disease history, using an statistically analytic method, such as the IBM Watson Analytics, may
improve the success to predict the probability the patient of developing advanced vulnerable
plaques.
The other commercial opportunities exist in using 64Cu-ATSM to target other hypoxic cells with
a patent before the disclosure, which is left for future studies.

131

Chapter 6: Conclusions
In this dissertation research, we showed the feasibility of

64

Cu-ATSM to identify hypoxic

atherosclerotic plaque in a genetically-altered mouse model. We fully validated the feasibility of
using 64Cu-ATSM to image the extent of hypoxia in a rabbit model of atherosclerotic-like plaques
using a simultaneous PET/MR system. Then we proceeded with a pilot clinical trial to determine
whether 64Cu-ATSM MR/PET scanning is capable of detecting hypoxic carotid atherosclerosis in
human subjects.
We investigated 4 partial volume correction methods to correct for partial volume effects and
incorporated the attenuation effect of the carotid surface coil to MR attenuation correction μ-map
to correct for photon attention.
In the long term, this imaging strategy will help identify patients at risk for cardiovascular events,
guide therapy, and study plaque biology in human patients.
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